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Abstract 
 
Viruses can trigger rheumatoid arthritis (RA) or inflammatory arthritis (IA). Our study 
provides insight into etiology of RA/IA. We analyzed the evidence relating to the risk of RA 
after viral infections; estimated the distribution of IA onsets over time; quantified the effect of 
influenza on the risk of IA.  
Results of systematic review and meta-analysis showed that the risk of RA/IA is increased 
after parvovirus B19 and chikungunya virus. There seems to be a risk of RA after chronic 
hepatitis C (HCV), but whether it is a true RA or HCV-associated arthritis is not clear. 
We estimated the distribution of IA onset for 10 years of observations using data from the 
Canadian Early Arthritis cohort of adults with incident early IA. We found that IA onset 
clusters in winter compared to other seasons. We applied time series regression analysis to 
estimate the effect of influenza time series on IA time series from 2010 to 2016. Influenza time 
series was based on laboratory confirmed influenza A and B cases retrieved from the Canadian 
FluWatch surveillance program. Our study showed on average 0.003% increase in IA onset 
with every influenza onset.  
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Chapter 1: Introduction 
 
1.1. Overall Goal 
The goal of this thesis was to improve our understanding of environmental risk factors 
in the etiology of rheumatoid arthritis (RA). Specifically, the aim of this research was to 
critically appraise the literature on the development of RA after different viral exposures. 
We also aimed to analyse the distribution of RA onsets over time, and studying the effect 
of influenza on the risk of RA.   
 
1.2. Background: An Introduction to Rheumatoid Arthritis 
RA is an autoimmune chronic inflammatory disorder. RA primarily affects joints, 
but a variety of extra-articular manifestations, such as skin, ocular, pulmonary, cardio-
vascular and renal manifestations, may also occur1. Inflammation in the joints, called 
arthritis, is characterized by synovial membrane proliferation and cartilage and bone 
destruction. Clinically, arthritis presents as pain, swelling, stiffness and limited motion in 
the joints.  Arthritis is usually symmetric and may affect large joints, such as shoulders, 
elbows, hips, knees, ankles, and small joints, such as wrists, metacarpophalangeal (MCP), 
proximal interphalangeal (PIP) and metatarsophalangeal (MTP) joints.  
 RA is considered to be the most common inflammatory arthritis in the world2. Over 
the past few decades, improved understanding of RA epidemiology and etiology has been 
complicated by the small number of studies, especially from developing and low-income 
countries, and significant differences in their methodological approaches3. In addition, 
earlier epidemiological studies estimated the frequency of RA using 1987 ACR 
classification criteria4, which later demonstrated poor sensitivity with regard to identifying 
patients with early inflammatory arthritis5. Despite the absence of robust estimates, and 
variability between geographic areas and patient populations, recent studies show RA 
prevalence to be about 0.5-1% of the general population, with female:male ratio of  2:1 to 
3:1 and an average onset at 50 years of age2,6–10. Approximately 25-50 new RA cases per 
2 
.  
100,000 population are diagnosed annually2.  
  In recent years, it has been repeatedly shown that the earlier and the more 
adequately RA is treated, the better prognosis a patient has11–13. If untreated, RA 
progresses, causing functional impairment, comorbidity, reduced health-related quality of 
life and premature death2. Moreover, the burden of RA is associated not only with direct 
medical expenditures, but with socio-economic aspects of life, such as reduced work 
capacity, productivity and social isolation, all resulting from functional disability14.  
       1.3 Etiology of Rheumatoid Arthritis 
           RA is an autoimmune disease with complex etiology, where immune, genetic, 
hormonal and environmental factors are involved15.  
           1.3.1 Immune System and Rheumatoid Arthritis 
            The immune system is a unique entity that defends the human body from invasions 
of various infectious agents using both innate and adaptive immunities. The role of innate 
immunity is to rapidly react and defend the human body from particular pathogens in the 
absence of prior immunologic experience with those pathogens. Adaptive or acquired 
immunity, comprises the activation of two types of lymphocytes – T- and B-cells, and 
either the elimination of the pathogen from the body or the prevention of its growth.  
The immune system, being complex, may start working abnormally if changes in 
its function occur. As a result, breakdown in normal self/non-self discrimination causes 
autoantibodies to attack self-organs and tissues, leading to the development of an 
autoimmune disorder. Autoimmune etiology of RA is supported by the presence of two 
types of autoantibodies in sera of patients with RA– rheumatoid factor (RF) and antibodies 
against citrullinated proteins (ACPA). RFs are a heterologous group of antibodies directed 
against the Fc-fragment of immunoglobulin G (IgG) antibodies. With approximately 60-
80% of patients with long-term RA being RF-positive, only 35-49% have RF in their serum 
from the disease onset16–18. Given moderate sensitivity, the specificity of RF is limited 
since it can be found in other autoimmune diseases and healthy individuals19. However, 
the specificity of RF improves with increases in its concentration, varying between 72-
3 
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95%20. ACPA is a relatively newly discovered type of autoantibody that reacts to peptides 
modified by the conversion of arginine to citrullin, leading to immune complex 
formation21. As opposed to RF, ACPA is considered to be extremely RA- specific (96-
98%) with relatively high sensitivity (68%-76%)22,23.  
1.3.2 Genetic Factors and Rheumatoid Arthritis 
         Familial aggregation of RA is considered to be a reliable indicator of disease 
heritability. According to the results from two nationwide studies of twins with RA, genetic 
factors are responsible for approximately 60% of a population’s liability to the disease, 
with no genetic input on disease across patients with different ages, sexes, ages at onset or 
disease severities 24,25. Given 60% attributable to genetic input, about 40% is left for non-
genetic contribution 26. 
          The association of RA with the human leucocyte antigen (HLA) genes was 
described by Stastny in 197627. Major histocompatibility complex (MHC) on chromosome 
6 is the place where the genes of HLA molecules are located. The major function of MHC 
is to participate in immune response. A number of studies have been carried out, showing 
that certain alleles carried by a specific locus of HLA-DR, termed “shared epitope”, are 
involved in the pathogenesis of almost exclusively ACPA-positive RA28–32.  For instance, 
relative risk (RR) for RA development is 4-5 times greater for those who carry two copies 
of shared epitopes compared to those who do not29,33. At present, heterogeneity in the 
number of genes involved in the development of the disease makes isolation of only one 
specific gene almost impossible34. The majority of discovered genetic risk factors are 
associated with seropositive for RF or ACPA RA and do not provide a complete picture of 
how genetics impact RA pathogenesis35. Therefore, the future of genetic research has 
potential with regard to identifying these unknown genetic factors.  
       1.3.3 Hormonal Factors and Rheumatoid Arthritis  
         The strongest evidence of the role of reproductive hormones in the development of 
RA is the higher incidence of RA in women. It was estimated that women who breastfed 
over 13 months had a two-fold lower risk of RA than those who breastfed for a shorter 
4 
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period 36. Another study found an association between early menopause and subsequent 
development of RA, implying the protective role of estrogens during the fertile period 37.  
        1.3.4 Environmental factors and RA 
         RA development can be triggered by different environmental exposures38. 
Therefore, successful prevention of RA very much depends on identification of all 
plausible environmental factors that may cause RA. However, one of the main obstacles in 
conducting studies in the environmental epidemiology is to collect accurate measurements 
of exposures that are relevant to the development of health-related outcomes. Therefore, 
environmental risk factors are either rarely discovered, or estimated based on studies with 
poor quality of evidence.  
         Environmental risk factors for RA conventionally can be divided into two major 
groups: lifestyle and purely environmental. Among lifestyle risk factors, such as smoking, 
coffee, alcohol consumption, diet and socio-economic factors, the cigarette smoking 
studies are considered to be the most methodologically strong and evidence-based. For 
instance, results from the UK twin registry show that, among 13 monozygote or dizygote 
twin pairs, the smoker was the twin with RA in 12 out of 13 cases39. Karlson et al. reported 
that, after adjustment for age, the RR for RA development among US female health 
professionals was 1.01 (95%CI 0.95; 1.08) for past smokers and 1.22 (95% CI 1.16–1.28) 
for current smokers, compared to never-smokers (p<0.01).  
         While cigarette smoking is considered to be a well-established RA risk factor, 
studies that have explored the relationship between dietary preferences, alcohol, coffee 
consumption and the risk of RA have inconclusive results, and this may be due to their 
poor quality40–44. By contrast, we have integral evidence that the adjusted odds ratio (OR) 
for RA development is on average 3.74 (95%CI 1.14; 12.27) for people with a body mass 
index (BMI) over 30 compared to those with BMI less than 3045.  
 
 
5 
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To date, among purely environmental factors, only silica dust exposure has been 
demonstrated as a risk factor for RA46,47. Researchers from the US examined the 
association of distance to roads as a proxy measure of exposure to traffic pollution with 
RA incidence. After adjustment for many potential confounders, the authors found that 
short-term risk of RA could be on average 31% higher in individuals living close to roads 
compared to those living a distance of 200m or more away (hazard ratio (HR) (95% CI) 
=1.31(0.98-1.74))48.  
         Infections are viewed as potent triggers of inflammatory arthritis/RA via 
mechanisms of infection-induced autoimmunity, such as molecular mimicry49–51. For 
instance, human parvovirus B19, Epstein-Barr virus and cytomegalovirus are considered 
to be risk factors of RA52,53. However, most of the studies that have attempted to link 
viruses with the development of inflammatory arthritis (IA) and RA were done many 
decades ago and suffer from inconsistent methodological quality. Therefore, it is not clear 
whether this is a non-random association or just chance.  
 1.4 Implications of this research 
  This research may clarify our understanding of the impact of environmental factors 
such as viruses in the development of RA. There is no currently published research that 
systematically analyzed the evidence relating to associations between different viral 
infections and RA. Our study may provide evidence that some viruses have clear 
association with RA, while others either have no association, or require attempted 
replications with more rigorous quality.  
 Another potentially unique finding of this research would be a demonstration of the 
seasonality of IA/RA onset from the prospective cohort study over a long period of 
observation. Knowledge that more IA/RA symptom onsets occur in winter, and that 
influenza can trigger IA/RA development, could help clinicians recognize this chronic 
debilitating disease at an early stage in the natural history. 
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1.5 The structure of this thesis 
 This thesis has an integrated-article format. Chapter 1 gives an introduction to RA 
and its etiology. Chapter 2 presents a systematic review and meta-analysis of viral risk 
factors for RA. Chapter 3 is a time series analysis of early IA onset and its possible 
association with influenza. Chapter 4 consists of summary of findings from previous 
chapters, strengths and weaknesses, conclusions, and future directions. The appendices 
present literature search strategy, data extraction details, quality and characteristics of the 
included studies, and publication bias assessment.   
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 Chapter 2: A Systematic Review and Meta-Analysis of Viral Exposures as Risk for 
Rheumatoid Arthritis  
Overview 
Rheumatoid arthritis is a chronic autoimmune disease causing joint pain and 
activity limitations. It is known that early RA diagnosis improves prognosis, which 
indicates the importance of early detection. Identifying groups at elevated risk of RA is 
thus one way to improve the detection of RA earlier in its natural history. In spite of the 
large public health burden of RA, we lack a complete understanding of etiologic factors, 
particularly the approximately up to 34% that are thought to be non-genetic environmental 
factors. The purpose of this chapter is to identify, summarize and critically appraise the 
evidence relating to the role of putative viral infections in the risk of RA.  
2.1 Introduction 
  Rheumatoid arthritis (RA) is considered the most common inflammatory arthritis. 
Over the past few decades, the development of the epidemiology of RA has been limited 
by the small number of studies, especially from developing and low-income countries, and 
by significant differences in their methodological approaches1. According to  1987 
American College of Rheumatology (ACR) classification criteria 2, the RA prevalence is 
0.5-1% in the general population, with female:male ratio of  2:1 to 3:1, average age at onset 
that has increased to approximately 50 years, and annual incidence of 25-50 cases per 
100,000 population3–8. 
In recent years, it has been repeatedly shown that early appropriate treatment 
improves the prognosis of RA9–11. Left untreated, RA progresses to cause functional 
impairment, reduced health-related quality of life and premature death5. RA is associated 
with increased costs including direct and indirect medical expenditures, and reduced work 
capacity 12. Therefore, the estimation of the risk factors of RA development is crucial to 
identify subgroups at increased risk and aid its recognition at early stages.  
RA is an autoimmune disease with a complex and poorly understood aetiology13. 
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Development of autoimmune disease stems from a combination of immune, 
genetic, hormonal and environmental factors14. Infections are viewed as triggers of some 
autoimmune disorders, including inflammatory arthritis15,16.  
There are five postulated mechanisms by which infections can trigger inflammatory 
arthritis. Molecular mimicry implies the production of cross-reactive antibodies to both 
pathogens and self-antigens as a consequence of the structural homology of the microbe 
and host molecules17. Epitope spreading is the second mechanism, where the pathogen-
induced inflammatory process contributes to increased processing and presentation of 
antigens by means of activation of antigen-presenting cells. As a result, exaggerated 
production of multi-targeted T-cells boosts an autoimmune response and development of 
the autoimmune disorder. The third is a B-cell-mediated pathway, where the infection of 
B-cells causes their proliferation, amplifying antibody and immune complex formation 
with self-tissues as a target. The fourth mechanism, called bystander activation, is a process 
of inflammation-triggered cytokine overproduction and subsequent increased formation of 
auto-reactive T-cells. Superantigens, produced by infections and causing non-specific T-
cell activation and subsequent cytokine release, repeatedly stimulate the immune system 
and autoimmune response 18.    
Many researchers have attempted to link different viruses with the development of 
inflammatory arthritis and RA. However, most of these studies were done many decades 
ago and have limitations in their methodological quality.  
The objective of this systematic review and meta-analysis (SRMA) is to evaluate, 
summarize and critically appraise the current evidence relating to the association between 
putative viral infections and the development of RA.  
 
2.2 Methods 
This SRMA is reported in accordance with the PRISMA guidelines19.   
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2.2.1 Inclusion and Exclusion Criteria 
We included full-text case-control and cohort studies published in English 
comparing the presence of different viral infections in adults (>18 years old) with and 
without RA, and with or without autoantibodies such as rheumatoid factor (RF) and/or 
antibodies against citrullinated proteins (ACPA). Cross-sectional and case-series studies 
were included if there was a lack of evidence from other study designs to assess the 
association between a virus and RA. For quantitative synthesis, we included studies with 
the minimum sample size of ten. For rare and relatively new viral infections we considered 
chronic inflammatory arthritis (joint pain, swelling and stiffness) as an alternative to RA 
as an outcome. Studies of patients with arthralgia after infection were excluded. No 
restrictions were placed on date or country of publication. We excluded non-human studies, 
review articles, editorials, commentaries and case-reports.  
2.2.2 Search Strategy 
We searched MEDLINE-OVID, EMBASE-OVID, CINAHL, PubMed and 
Cochrane Library databases. We also searched the abstract archives for EULAR and ACR 
meetings years 2000-2017. A comprehensive search strategy was developed under the 
guidance of a medical reference librarian using MeSH terms, keywords and Boolean 
operators (see Appendix A, Table A-1 for detailed strategy and search results). Searches 
were performed in July 2017 and updated in September 2017.  
2.2.3 Study Selection 
All study records were imported into Covidence (Covidence systematic review 
software, Veritas Health Innovation, Melbourne, Australia). After the removal of 
duplicates, two reviewers (FK and MS) independently screened titles, abstracts and full-
texts of the records for eligibility. Disagreements were resolved by consensus.  
2.2.4 Data Extraction 
One reviewer (FK) extracted the following information from the included studies: 
study details (author, year, study location, design), baseline characteristics (population, 
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sample size), type of virus, viral antibodies, values of seropositivity, and main findings.  
2.2.5 Study Quality 
One reviewer (FK) assessed the methodological quality of studies included in 
systematic review using the Downs and Black checklist. This checklist is a validated tool 
to assess the quality of randomized and non-randomized (observational) trials 20–23. For the 
purposes of this review, we modified the original 27-item checklist excluding the items 
related specifically to interventional studies, such as random assignment, blinding of 
patients, description of interventions, adverse events and retention rate. As a result, the 
checklist was reduced to 17 items comprising five original domains: reporting (6 items), 
external validity (3 items), bias (4 items), confounding (3 items) and power (1 item). Each 
item has score 0 (no/unable to determine) or 1 (yes). Maximum score of 17 could be 
achieved, with higher scores reflecting the better methodological quality of the studies 
(Table 2-1).  
2.2.6 Summary Measures and Synthesis of Results 
Meta-analysis was conducted using Review Manager V.5.024. Data were presented as 
odds ratios (OR) of seropositivity to viruses for case-controls studies, and ORs and hazard 
ratios (HR) of RA development and/or autoantibodies formation for cohort studies. All 
analyses were conducted using the Mantel-Haenszel random-effects model given the 
assumption that the true effect sizes may vary from study to study. Heterogeneity of the 
results was assessed using p-values from the chi-squared test which measures how well the 
observed distribution fits with the expected distribution, and with the I2 that is a descriptive 
statistic measuring inconsistency across studies (0-30% low; 31-50% moderate; >50% 
high).  We used 95% confidence interval (95% CI) and 0.05 level of significance to report 
the study results. Subgroup analyses were performed for case-control studies where 
matching of cases and controls was applied. Funnel plots were calculated to assess 
publication bias (The Cochrane Collaboration, 2008).  
 
2.3 Results 
2.3.1 Study Selection and Quality  
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A total of 6724 references were identified (4174 from MEDLINE-Ovid, 750 from 
EMBASE-Ovid, 30 from CINAHL and 1770 from PubMed and Cochrane library) and 
imported into Covidence. After removing 1946 duplicates, 318 studies were eligible for 
full-text review (Appendix A, Table A-1). Seventy-eight studies including fifteen studies 
added by backward citation met the eligibility criteria and were included in the qualitative 
synthesis. Forty-eight studies were included in quantitative synthesis. Among included 
studies, sixty-two were case-control, eight were case-series, five were cross-sectional, and 
three were cohort studies. The studies were published between 1965 and 2017. The quality 
assessment of the included studies is presented in Table 2-1. Briefly, only two studies 
reached the score of 16. Thirty-seven studies had good quality with a score range 12-15. 
Half of the studies (n=39) had poor quality with the score of 11 or less. Two studies 
attempted to blind exposure assessors. Sample size or power calculations were done in two 
studies. A full quality assessment report is presented in Appendix B (Table B-1). 
2.3.2 Summary of Findings 
In total, the following thirteen viruses were identified in association with RA 
development and/or RF/ACPA autoantibodies formation: human parvovirus B19 (PVB19), 
Epstein-Barr virus (EBV), chronic hepatitis B (HBV) and C (HCV), cytomegalovirus 
(CMV), human herpes virus (HHV), human endogenous retrovirus (HERV), herpes 
simplex virus (HSV), varicella zoster virus (VZV), rubella virus, measles, chikungunya 
virus (CHIKV), and Asian influenza. The main characteristics and findings of the studies 
are presented in Appendix C (Table C-1, C-2).  
Human Parvovirus B19 
Sixteen case-control studies explored the association between PVB19 and RA 
based on the presence of PVB19 immunoglobulin (Ig) G, IgM antibodies in sera and/or 
viral deoxyribonucleic acid (DNA) in sera or synovial fluid/membrane of patients with RA 
and controls. Three studies provided no diagnostic criteria for RA25–27. Controls were 
healthy subjects in eleven studies, and patients with various joint disorders in five studies. 
One study used age-matching of cases and controls28, two studies applied age- and sex-
matching29,30, and two studies used  3 factors to match cases and controls31,32. Values of 
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seropositivity for anti-PVB19 antibodies were specified only in three studies28,31,32.  
         Three studies were excluded from the meta-analysis: Casinotti et al.27 used a small 
and heterogeneous comparison group, Nikkari et al.33 estimated antibodies’ prevalence in 
synovial fluid and peripheral blood mononuclear cells (PBMC) in controls, and Pugliese 
et al.26 had a small case group. 
IgG antibodies to Parvovirus B19 
         Eleven studies reported the prevalence of IgG anti-PVB19 antibodies, including 
1616 cases and 1494 controls in total25,28–32,34,35,37–39. Cumulative odds of IgG anti-PVB19 
antibodies detection were significantly higher in RA patients compared to controls (OR 
(95% CI) = 1.76 (1.09; 2.84), p=0.02), with high degree of heterogeneity (I2 = 78%, 
p<0.00001) (Figure 2-1). Restriction of the analysis to matched at least for age case-control 
studies (1379 cases and 1196 controls) resulted in a statistically significant cumulative odds 
ratio (OR (95% CI) = 2.22 (1.04; 4.75), p=0.04) with high heterogeneity (I2 = 89%, 
p<0.00001) (Figure 2-2). 
IgM antibodies to Parvovirus B19    
         Six studies reported the prevalence of IgM antibodies, indicating recent PVB19 
infection, in 295 RA patients and 319 controls25,29,34,35,37,38. Cumulative odds ratio was 
insignificant (OR (95% CI) = 1.77 (0.68; 4.59), p=0.24), with moderate heterogeneity (I2 
= 35%, p=0.19) (Figure 2-3). We did not perform a subgroup analysis because only one 
study used matching of cases and controls29.  
         Parvovirus B19 DNA 
          Seven studies in total estimated the presence of PVB19 DNA in cases and 
controls29,30,34,36,38–40. Four studies were excluded from the meta-analysis: one had no data 
on viral DNA in the comparison group34, one had unclear methodology section where cases 
and controls could not be identified correctly40, and two estimated DNA in synovium and 
synovial fluid only36,38. Three remaining studies with 215 cases and 148 controls resulted 
in cumulative odds of PVB19 DNA of OR (95% CI) = 3.53 (1.00; 12.53), p=0.05, with 
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high heterogeneity (I2 =62%, p=0.07) (Figure 2-4). Subgroup analysis was not performed 
because only two studies matched cases with controls29,30.  
 Epstein-Barr virus 
In total, thirty-two case-control studies compared the presence and/or geometric 
mean titers of anti-EBV antibodies against Epstein-Barr nuclear antigen (EBNA), viral 
capsid antigen (VCA), and early antigen (EA) in sera and/or synovial samples of RA 
patients and controls.  Three studies provided no diagnostic criteria for RA41–43. Controls 
were healthy subjects, except for four studies where patients with various joint disorders 
served as controls. Eleven studies used matching of cases and controls: Luneman et al.44 
used only age-matching, six studies applied age- and sex-matching45–50, and four studies 
used  3 factors to match cases and controls31,32,51,52. Values of seropositivity for anti-EBV 
antibodies were specified in twelve studies31,46,59,50,51,53–58. Six studies were not included in 
quantitative synthesis with reasons. Henle et al. and Draborg et al. looked at the prevalence 
of only serum IgM and IgA anti-EBV antibodies, respectively54,56. Two studies did not 
specify the type of anti-EBV antibodies measured48,60. One study looked at EBV viral 
antibodies only in synovial fluid61. One study estimated EBV DNA prevalence  in serum 
and PBMC62. One study reported only titers of anti-EBV antibodies47.  
 Epstein-Barr nuclear antigen IgG antibodies 
Seventeen studies measured the prevalence of IgG anti-EBNA antibodies with 1165 
RA cases and 1088 controls31,41,59,63–68,44–46,49,51–53,55. Alspaugh et al. and Musiani et al. 
applied relatively high cut-off levels for EBNA IgG seropositivity (1/320)46,53. 
Cumulative odds of anti-EBNA detection were comparable between RA patients and 
controls (OR (95% CI) = 1.05 (0.79; 1.39), p=0.75), with low heterogeneity (I2 = 8%, 
p=0.36) (Figure 2-5).  
Restriction of the analysis to studies with at least age-matched cases and controls 
resulted in a cumulative sample size of 417 and 621 for RA and controls, respectively, and 
not significant cumulative odds ratio with low heterogeneity (OR (95% CI) = 1.04 (0.7; 
1.54), p=0.84, I2 =0%, p=0.46) (Figure 2-6). 
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Epstein-Barr viral capsid antigen IgG antibodies 
  Eighteen studies estimated the presence of IgG anti-VCA antibodies, including a 
total of 2046 cases and 1682 controls31,32,57,58,65,66,68–71,41,44–46,49,51,53,55. Alspaugh et al. 
considered a relatively high titer of anti-VCA IgG antibodies as  being positive  (1/320)53. 
Even though none of the individual studies showed statistically significant differences in 
the detection of anti-VCA antibodies between the groups, the cumulative odds of anti-VCA 
seropositivity were significantly higher in RA patients than in controls (OR (95% CI) = 1.5 
(1.07; 2.10), p=0.02), with low heterogeneity (I2 = 14%, p=0.29) (Figure 2-7).  
Seven studies used at least age-matching in a total of 277 cases and 478 controls. 
No significant difference was observed between the cumulative odds of anti-VCA IgG 
seroprevalence in RA patients and controls (OR (95% CI) = 1.20 (0.35; 4.12), p=0.77) 
(Figure 2-8). Only four studies contributed to the overall effect estimate, and demonstrated 
high heterogeneity (I2 =61%, p=0.03).  
Epstein-Barr early antigen IgG antibodies 
  Eleven studies reported the prevalence of anti-EA IgG antibodies, including 737 
cases and 536 controls41,44,70,45,46,50,51,55,59,65,68. Cumulative odds of serum anti-EA 
antibodies were statistically significantly higher in RA patients than in controls (OR (95% 
CI) = 2.74 (1.27: 5.94), p=0.01), with high heterogeneity (I2 = 79%, p<0.001) (Figure 2-9).  
Five studies used matching, resulting a total of 226 cases and 227 controls and 
significant cumulative odds ratio (OR (95%CI) = 7.38 (1.33; 40.94), p=0.02) with high 
degree of heterogeneity (I2 = 85%, p<0.000001) (Figure 2-10).  
 Cytomegalovirus 
  Thirteen studies estimated the presence of anti-CMV antibodies in patients with RA 
and control subjects32,41,64,65,72,43,44,46,48,51,57,61,62. Five studies used matching of cases and 
controls32,44,46,48,51. Five studies reported cut-off values of seropositivity for anti-CMV 
antibodies32,46,51,57,72. Four studies were excluded from the quantitative synthesis with 
reasons: serum was tested only for viral DNA62, small number of patients were tested for 
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anti-CMV antibodies43, serum anti-CMV antibodies were detected only in patients positive 
for CMV DNA61, and anti-CMV were not estimated in normal controls48. Analysis of nine 
studies, including 1456 cases and 1078 controls, resulted in comparable cumulative odds 
of anti-CMV seropositivity in RA patients and controls (OR (95% CI) = 1.19 (0.79; 1.78), 
p=0.42), with 55% of heterogeneity (Figure 2-11).   Subgroup analysis including four 
studies with matching cases and controls resulted in not significant cumulative odds ratio 
(OR (95% CI) = 1.61 (0.73; 3.55), p=0.24, I2 = 79%, p=0.02) (Figure is not presented).  
Chronic hepatitis B 
Seven studies in total evaluated the association between chronic hepatitis B and 
RA. One study did not specify the diagnostic criteria for RA73. Controls were healthy 
subjects, except one study where patients with ankylosing spondylitis served as controls74. 
None of the studies used matching of cases and controls.  
Five case-control studies provided data comparing the prevalence of hepatitis B in 
619,140 RA patients and 37,577,194 controls73–77. The cumulative odds ratio of HBV 
infection was not statistically significant (OR (95% CI) = 1.37 (0.83; 2.25), p=0.22) with 
high degree of heterogeneity (I2 = 100%) (Figure 2-12). After we excluded the study of 
Yilmaz et al.74, where patients with ankylosing spondylitis served as controls, the 
association remained not significant (OR (95% CI) = 1.64 (0.93; 2.89), p=0.09, I2 = 100%, 
p<0.0001) (Figure is not presented). 
Two included studies applied multivariable logistic regression to control for 
potential confounding factors in the association between RA and HBV. Hsu et al. reported 
an increased risk of HBV infection in RA compared to non-RA individuals (adjusted OR 
(95% CI) = 1.13 (1.08; 1.17), p<0.001)77. Jeong et al  estimated significant odds ratio for 
HBV infection in RA patients compared to controls (adjusted OR (95% CI) = 2.34 (1.15; 
4.80), p=0.02)73. 
Shim et al. in a cross-sectional study estimated that the prevalence of RF in patients 
with HBV infection and healthy screening subjects without HBs-antigens (Ag), both RA-
free, was 11.8% and 3.4%, respectively (p<0.001). The presence of HBs-Ag in healthy 
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subjects was associated with on average 3.82-fold (95% CI (3.22; 4.53), p<0.001) increase 
for RF seropositivity when compared with HBs-Ag negative healthy subjects78. 
Su et al. in their cohort study estimated that after adjusting for potential 
confounders, short-term risk of RA development was comparable between patients with 
HBV infection (n=35,652) and HBV-free individuals (n=199,568) (hazard ratio (HR) (95% 
CI) = 1.09 (0.74; 1.63), p>0.05)79.  
Chronic hepatitis C 
Ten studies in total evaluated the association between chronic hepatitis C and RA. 
Three studies did not specify the diagnostic criteria for RA73,80,81. Controls were healthy 
subjects, except in three studies where patients with different rheumatic disorders served 
as controls74,81,82. None of the studies used matching of cases and controls.  
Seven case-control studies compared the presence of chronic hepatitis C in 580,695 
RA cases and 36,880,519 controls73,74,80–84.  The cumulative odds of HCV detection were 
on average 2.82-times higher in patients with RA compared to controls (OR (95% CI) = 
2.82 (1.35; 5.90), p=0.006), with heterogeneity of 67% (Figure 2-13). After we excluded 
the study of Yilmaz et al., with ankylosing spondylitis controls, the association remained 
significant (OR (95% CI) = 4.16 (1.56; 11.14), p=0.006, I2 = 67%, p=0.006) (Figure is not 
presented). 
Two studies used multivariable logistic regression to control for potential 
confounders in the association between HCV and RA. Jeong et al. and Hsu et al. estimated 
not significant odds ratios for HCV infection in RA patients compared to controls (adjusted 
OR (95% CI) = 1.47 (0.18; 11.80), p=0.714; adjusted OR (95% CI) = 0.44 (0.07; 2.80), 
p=0.37, respectively)73,83. Two cross-sectional studies determined the prevalence of HCV-
associated inflammatory arthritis among HCV infected population. Ferucci et al. found 
6.8% prevalence of HCV-associated inflammatory arthritis, but similar frequency of RF-
positivity among individuals with HCV arthritis (n=8) and no inflammatory arthritis groups 
(n=105) (38% vs 39%, respectively, no p-value)85. Cacoub et al. reported 2% prevalence 
of persistent arthritis among 321 HCV-infected individuals, with one confirmed RA. They 
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also found that the odds of RF-positivity were on average 2.79 higher in cryoglobulin-
positive compared to cryoglobulin-negative HCV patients (adjusted OR (95% CI) = 2.79 
(1.21; 6.41), p=0.01)86.  
In a cohort study Su et al. estimated that adjusted for potential confounders short-
term risk of RA development is on average 2.03-times higher in patients with chronic HCV 
infection (n=10,253) compared to HCV-free individuals (n=199,568) (adjusted HR (95% 
CI) = 2.03 (1.27; 3.22), p<0.01)79.  
Chronic hepatitis B and C infection 
Short-term risk of RA development was marginally higher in patients with both 
HBV and HCV infections compared to non-infected individuals (adjusted HR (95%CI) 
=1.92 (0.94, 3.92), p>0.05)79.  
Chikungunya virus 
Eleven studies reported data on chikungunya virus (CHIKV) -associated 
inflammatory arthritis/RA; eight were case-series87–93,  two were cross-sectional94,95 and 
one was cohort96. The results from case-series and cross-sectional studies are summarized 
in Table 2-2. Six studies reported the development of mostly RF-negative RA after 
CHIKV. Essackjee et al. also found that age >50 years and a symmetrical arthritis at 
baseline were significantly associated with the development of RA (adjusted OR (95% CI) 
= 90 (15.2; 134.3), p=0.047 for age; 5% vs 100% for symmetrical arthritis, p<0.0001, for 
patients not fulfilling and fulfilling RA criteria, respectively)95. A cohort study by Yaseen 
et al. showed that the odds of arthritis were on average 26.75 times higher in CHIKV-
positive compared to CHIKV-negative individuals (adjusted OR (95% CI) = 26.75 (11.15; 
64.17), p<0.005) on average 30 months post-infection. They also found a significant 
association between comorbidity (sprain or dislocation of joints or bones and joint 
diseases) before CHIKV infection and the development of arthritis (adjusted OR (95% CI) 
= 2.47 (1.19; 5.14), p<0.05)96.  
Human herpes virus 6 
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  Mousavi-Jazi et al. estimated not significant odds for HHV-6 IgG antibodies (OR 
(95% CI) = 0.82 (0.3; 2.2), p=0.69) in RA compared to controls65. Alvarez-Lafuente 
reported HHV-6 serum viral loads in patients with RA and controls (0-529.1 vs  0, 
respectively, p=0.007)62.  
Varicella zoster virus 
  Three studies estimated IgG anti-VZV antibodies in RA patients and controls43,64,65. 
Catalano et al. found similar geometric mean titers of anti-VZV antibodies in cases and 
controls (7.21.4 and 7.31.5, respectively). No matching of cases and controls was done. 
The cumulative odds ratio from the two studies was not significant (OR (95% CI) = 1.77 
(0.48; 6.51), p=0.39) (Figure 2-14).  
 Rubella virus 
  Based on the two studies that used matching of cases and controls49,97, the 
cumulative odds ratio of serum anti-rubella IgG antibodies was insignificant (OR (95% CI) 
= 1.78 (0.22; 14.54), p=0.59, I2 = 0%, p=0.6) (Figure 2-15).  
Herpes simplex virus type-I 
  Mousavi-Jazi et al found comparable odds of anti-HSV antibodies in RA and 
controls (OR (95% CI) = 0.79 (0.3; 2.08), p=0.63)65. Catalano et al found lower geometric 
mean titers of anti-HSV antibodies in cases than in controls (4.02.6 and 5.11.6, 
respectively)43. 
Measles  
  Shirodaria et al found anti-measles IgG antibodies in sera of  all RA patients (n=26) 
and controls (n=26)49. 
Human endogenous retrovirus 
  Ejtehadi et al. performed ribonucleic acid (RNA) HERV extraction from PBMC 
and concluded a statistically significant increase in HERV expression level in RA patients 
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compared to controls (27/40 of RA cases, p=0.01) although no data on controls was given98.  
Influenza virus 
Svec et al. in a prospective cohort study found that, among age and sex-comparable 
subjects examined right after epidemic spread of influenza A, there was a significant odds 
ratio of being RF-positive in subjects with the presence of anti-influenza antibodies  
compared to  subjects without anti-influenza antibodies (OR (95% CI) = 13.6 (1.4; 127.4), 
p=0.02)99.   
Unspecified infections 
Two studies used self-reported questionnaires to explore the odds of unspecified 
respiratory tract infections in patients with RA compared to controls and were not included 
in meta-analyses. Vandenbroucke et al estimated that the odds of preceding 
bronchopulmonary infection did not significantly differ between patients with RA and 
controls (adjusted OR (95%CI) = 0.76 (0.53; 1.07)100. Similarly, Sandberg et al found that 
after adjustment for socio-economic status (SES) and smoking, the odds of prior respiratory 
tract infections did not significantly differ between patients with RA and controls (adjusted 
OR (95%CI) = 0.96 (0.82, 1.13) for sinusitis, 0.99 (0.86, 1.14) for tonsillitis, and 1.03 (0.73, 
1.45) for pneumonia). However, the odds of reported history of sinusitis were marginally 
significantly higher in patients with ACPA-negative compared to ACPA-positive RA 
(adjusted OR (95%CI) = 1.31 (1.00, 1.71) for ACPA-negative RA, and 0.78 (0.64; 0.96) 
for ACPA-positive RA).  
2.3.3 Publication Bias 
  Funnel plots were used to assess publication bias.  We followed the 
recommendation not to use funnel plots in case when less than 10 studies are included in 
meta-analysis because of the low power to exclude chance as a cause of asymmetry101. 
Funnel plots for anti-PVB19 IgG antibodies, anti-EBNA IgG, anti-VCA IgG and anti-EA 
IgG (Appendix D, Figures D-1, D-2, D-3, D-4, correspondingly) suggest a low risk of 
publication bias, though smaller studies are missing at the bottom of the funnel plot for 
anti-PVB IgG antibodies. However, because not only publication bias but heterogeneity 
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and chance may explain non-symmetric funnel plots, funnel plots should be cautiously 
interpreted102,103.    
 
2.4  Discussion 
This systematic review and meta-analysis is the first to our knowledge that attempted 
to evaluate, summarize and critically appraise the current evidence of an association 
between different viral infections and the development of RA.  
Among thirteen viruses that were identified in the association with RA development 
and/or RF/ACPA autoantibodies formation, seven viruses were meta-analyzed: PVB19, 
EBV, CMV, HBV, HCV, VZV, and rubella virus. Overall, there were seven statistically 
significant pooled estimates. Pooled estimates had the highest size range in subgroup 
analysis for anti-EA IgG EBV antibodies (7-fold increase) and the lowest size range for 
anti-VCA IgG EBV antibodies (1.5-fold increase).  
The majority of the studies were case-control and measured the association between 
viruses and RA based on the presence of anti-viral antibodies in sera of RA patients and 
control subjects. Overall, half of the studies had poor quality attributable to the lack of 
external and internal (confounding) validity.  Only fifteen studies defined cut-off levels of 
seropositivity for viral antibodies.  Moreover, there was a variability of seropositivity 
among studies.  The use of matching to minimize confounding was insufficient: out of 
eighteen studies, four studies used only age to match cases and controls.  
We found a significant association between RA and serological markers of PVB19 
infection, particularly, serum anti-PVB19 IgG and serum PVB19 DNA. Found in both 
active and recent infections, but rare in healthy individuals, the persistence of PVB19 DNA 
in the blood is considered a reliable method of PVB19 detection104. No significant 
association between RA and anti-PVB19 IgM, indicative of current or recent infection was 
found.  The forest plots had moderate to high degrees of heterogeneity and the direction of 
effect across studies was inconsistent, possibly attributable to small sample sizes in most 
studies and a small number of PVB19 positive subjects which resulted in wide confidence 
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intervals. After restriction of the analysis to studies with the matching of cases and controls 
(for PVB19 IgG), an association between RA and PVB19 remained significant, though 
with a high degree of heterogeneity.  
We failed to find a significant association between RA and anti-EBNA IgG antibodies, 
even in the subgroup analysis with matched cases and controls. A large number of studies 
contributed to the pooled effect estimate, with low heterogeneity. Consistent direction of 
effect between studies suggests the absence of the association between anti-EBNA 
antibodies and RA. By contrast, significant associations between RA and anti-VCA IgG, 
and RA and anti-EA IgG antibodies have been found. The association for anti-VCA 
became not significant after we excluded the studies without matching of RA cases and 
controls. As for anti-EA antibodies, a significant association with RA remained after 
matched studies were analyzed. However, due to limitations of meta-analysis, such as a 
small number of studies with matching, small sample sizes and variability in cut-off levels 
of anti-EA seropositivity, we observed high heterogeneity in the direction of the effect 
between some studies.  It is thought that anti-EBNA and anti-VCA IgG antibodies imply 
the past EBV infection, while high titers of EA antibodies are indicative of persistent or 
reactivated EBV infection, especially in immunocompromised individuals105.  At the same 
time, there is evidence that all three serological markers of EBV may be found 
simultaneously both in the past and recent/reactivated EBV infection106. Our results are 
somewhat similar to the results of Ball et al., who failed to find a significant association 
between either of three EBV antibodies and RA107.  
There is compelling evidence that RA is not associated with CMV infection. The forest 
plot demonstrated consistency among the studies and cumulative odds ratio with a precise 
confidence interval. 
Our results did not demonstrate significantly different odds of HBV infection among 
RA patients and controls. The pooled results had high heterogeneity that could be 
attributable to the small number of studies, and poor methodology including a small 
number of patients with positive HBs-Ag in each group in one study76.  The authors from 
Taiwan in their 11-year cohort study found no evidence to support the hypothesis about the 
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increased risk of RA in HBV-infected patients, who were free of any autoimmune disease 
at baseline79. Interestingly, another study from Taiwan, using the same study population 
and similar methods, did find a significant association between HBV infection and RA, 
and an increased incidence rate ratio for HBV infection between the RA and non-RA 
cohorts77.  On a par with the latter result, a large population-based Korean study estimated 
the increased adjusted odds of HBV infection in RA patients compared to controls84. 
However, the authors used self-reports as a source of information with regards to all 
diagnoses and did not apply RA criteria, therefore limiting the interpretation. Interestingly, 
Shim et al estimated an association between the presence of HBs-Ag and RF-formation, 
and a higher prevalence of RF in HBV patients than controls78.  
We found that HCV infection was significantly associated with RA but not all studies 
were positive. Similarly, Su et al in their cohort study estimated that patients with HCV are 
at double risk of RA compared to controls79. By contrast, the two studies that were included 
in the quantitative synthesis failed to find a significant association of HCV infection with 
RA after adjustment for many potential confounders73,83. A postulated mechanism of HCV-
induced inflammatory arthritis is mediated through HCV mixed cryoglobulinemia, where 
possible persistence of HCV infection in B-lymphocytes leads to the production of mixed 
cryoglobulins, monoclonal IgM RF and polyclonal IgG (anti-HCV), representing the 
source of repetitive stimulations of the immune system108,109. Based on the results of 
Cacoub et al, who found a significant association between the presence of mixed 
cryoglobulins in HCV patients and RF in RA-free individuals, it is possible that 
cryoglobulin is the main factor that is responsible for the development of RA in HCV 
cryoglobulin-positive individuals86,110. However, there also could be misclassification via 
labelling HCV infection with arthritis and a positive RF as RA.  
The coincidence of HBV and HCV infection seems to be marginally associated with 
the increased risk of RA, based on the results from one large cohort study 79.  
  The majority of the studies that explored a possible association between CHIKV 
and RA have poor methodological quality. The results from case-series and cross-sectional 
studies showed that the risk of RA, mostly RF-negative, after CHIKV is low. On the other 
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hand, one methodologically strong study determined that older age (>50 years) and 
symmetrical arthritis at baseline were significantly associated with the development of RA 
after CHIKV95. Another cohort study found that CHIKV-positive patients were at 
significant risk of arthritis (defined as joint swelling, pain and/or stiffness, regardless of 
the number of joints involved) compared to CHIKV-negative individuals (adjusted OR 
(95% CI) = 26.75 (11.15; 64.17), p<0.005). This association became even stronger if 
patients had a prior to CHIKV joint involvement (adjusted OR (95% CI) = 2.47 (1.19; 
5.14), p<0.05)96. However, there could be misclassification of chronic viral/post viral 
arthritis and actual RA where the latter could be more destructive.  
  Analyses of the risk between patient-reported unspecified respiratory tract infection 
and RA failed to find any significant association. However, limitations of these studies 
such as reporting bias, absence of serologically confirmed infections, do not preclude a 
possible link between respiratory infections and RA. We also looked at the association 
between HHV, HERV, HSV, VZV, rubella virus, measles, and Asian influenza and the 
risk of RA. Due to a small number of studies and the absence of cohort studies, none of the 
viruses could be linked with RA development.  
 
2.5 Conclusions 
  Studies about the risk of RA after viral exposures suffer from inconsistent 
methodological quality. The risk of RA could be increased after PVB19. There seem to be 
a risk of RA after HCV infections, but whether it is a true RA or HCV-associated arthritis 
is not clear.  The risk of RA is not increased after EBV and CMV infections. There is 
uncertainty about the risk of RA in patients with HBV. CHIKV is mostly associated with 
the development of a persistent inflammatory arthritis. There is not enough evidence to 
support an association between some viruses and RA development, but they probably lead 
to RA in genetically susceptible individuals.  
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Table 2-1. The quality of included studies.  
Author (publication) Year Journal Quality*  
Caliskan R et al.34  2005 Rheumatology International 11 
Cassinotti P et al.27  1995 Annals of Rheumatic Diseases 7 
Chen Y-S et al.29  2006 Journal of Rheumatology 14 
Cohen B et al .38  1986 Annals of Rheumatic Diseases 12 
Hajeer A et al.28  1994 Annals of Rheumatic Diseases 11 
Jobanputra P et al.40  1995 British Medical Journal 13 
Kerr J et al.37  1995 British Journal of Rheumatology 10 
Kozireva S et al.35  2008 Journal of Rheumatology 12 
Naciute M et al.30  2016 The Journal of General Virology 14 
Nikkari S et al.33  1995 Annals of Rheumatic Diseases 11 
Pugliese A et al.26  2007 Cell biochemistry and function 10 
Saal J et al.36  1992 Rheumatology International 12 
Takahashi Y et al.39  1998 Proceedings of the National Academy of 
Sciences of the United States of America 
8 
Taylor H et al.25  1992 Clinical Rheumatology 12 
Sherina N et al.32  2017 Arthritis Research & Therapy 15 
Alspaugh M et al.53  1981 The Journal of Clinical Investigation 7 
Alvarez-Lafuente R et al.62  2005 Annals of Rheumatic Diseases 13 
Balandraud N et al.60  2003 Arthritis and Rheumatism 13 
Blaschke S et al.45  2000 The Journal of Rheumatology 14 
Catalano M et al.43  1979 Proceedings of the National Academy of 
Sciences of the United States of America 
11 
Davies J et al.63  1999 Autoimmunity 11 
Draborg A et al.54  2012 Scandinavian Journal of Rheumatology 13 
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Ferraro A et al.64  1993 Clinical and Experimental Immunology 13 
Ferrell P et al.55  1981 The Journal of Clinical Investigation 11 
Goldstein B et al.51  2012 Autoimmunity 15 
Henle G et al.56  1979 Clinical and Experimental Immunology 5 
Jorgensen K et al.31  2008 Annals of Rheumatic Diseases 13 
Lunemann J et al.44  2008 Journal of Immunology 12 
Meron M et al.41  2010 Clinical Rev in Allergy and Immunology 9 
Male D et al.72  1982 Clinical and Experimental Immunology 13 
Mehraein Y et al.61  2004 Modern Pathology 11 
McDermott M et al.42  1989 Irish Journal of Medical Science 11 
Mousavi-Jazi M et al.65  1998 Journal of Rheumatology 11 
Musiani M et al.46  1987 Annals of Rheumatic Diseases 11 
Nakabayashi K et al.47  1985 Rheumatology International 11 
Ng K et al.66  1980 Lancet 9 
Phillips P et al.48  1976 Annals of Rheumatic Diseases 10 
Saal J et al.69  1999 Arthritis & Rheumatism 14 
Sculley T et al.67  1986 Arthritis & Rheumatism 12 
Shirodaria P et al.49  1987 Archives of Neurology 11 
Silverman S et al.50  1981 Arthritis & Rheumatism 10 
Venables P et al.58  1981 Arthritis & Rheumatism 11 
Venables P et al.57  1985 Annals of Rheumatic Diseases 11 
Westergaard M et al.59  2015 BioMed Research International 11 
Yao Q et al.70  1986 Clinical and Experimental Immunology 10 
Yazbek M et al.52  2011 Clinics 11 
Youinou P et al.68  1992 Autoimmunity 11 
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.  
Zhang L et al.71  1993 Arthritis & Rheumatism 9 
Vandenbroucke J et al.100  1987 Arthritis & Rheumatism 14 
Sandberg M et al.111  2015 Annals of Rheumatic Diseases 14 
Bosma t et al.97  1998 Journal of clinical microbiology 8 
Ejtehadi H et al.98  2006 Annals of Rheumatic Diseases 10 
Adebajo A et al.75  1993 Clinical Rheumatology 8 
Barbosa V et al.81  2005 Revista Brasileira de Reumatologia 10 
D'Amico E et al.82  1996 Journal of Clin Rheumatology  12 
Hoofnacle J et al.76  1974 The Amer Journ of the Med Sciences 11 
Hsu F et al.83  2003 Journal of Rheumatology 15 
Hsu C-S et al.77  2016 Medicine 15 
Jeong  H et al.73  2016 Arthritis & Rheumatology 15 
Park Y et al.80  1991 Gastroenterologia Japonica 12 
Rivera J et al.84  1999 Journal of Rheumatology 14 
Yilmaz N et al.74  2014 European Journal of Rheumatology 13 
Ferucci E et al.85  2017 Seminars in Arthritis and Rheumatism 15 
Su F-H et al.79  2014 PloS one 13 
Cacoub P et al.86  2000 Medicine 15 
Shim C et al.78  2012 Modern Rheumatology 15 
Essackjee K et al.95  2013 Postgraduate Medical Journal 16 
Bouquillard E et al.112  2009 Joint Bone Spine 8 
Duran A et al.94  2017 Annals of Rheumatic Diseases 14 
Kularatne S et al.89  2012 Journal of Tropical Medicine 12 
Manimunda S et al.90  2010 Transactions of the Royal Society of 
Tropical Medicine and Hygiene 
13 
42 
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Gauri  et al.87  2016 Inter J of Advanced Research and Review 11 
Javelle E et al.88  2015 PLoS Neglected Tropical Diseases 11 
Rosario R et al.92  2015 Clinical Rheumatology 6 
Miner J et al.91  2015 Arthritis & Rheumatology 11 
Sepulveda-Delgado J et al.93  2017 Clinical Rheumatology 13 
Yaseen H et al.96  2014 BMC Musculosceletal Disorders 16 
Svec K et al.99  1965 Arthritis & Rheumatism 14 
* The Downs and Black quality assessment checklist. Maximum score is 17  
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Table 2-2. Case-series and cross-sectional studies on Chikungunya-associated arthritis. 
Study ID 
Sample 
size 
CHIKV 
polyarthritis 
(symmetrical 
pain, joint  
swelling), n 
Time since 
CHIKV,  
months 
Medical 
history of 
arthritis, n 
RA,  
n 
Resolved 
arthritis,  
n 
Bouquillard 2009 21 21 
Mean 10 
(range 4-
18) 
NK 
21  
(12 RF+) 
None 
Duran 2017 202 72 
9140 days 13 (RA or 
other 
autoimmune 
disease) 
6 (RF+), 
66 -UA 
(RF-) 
NK 
Essackjee 2013 195 34  
Median 
27.5 
NK 
10 (ACR 
1987) 
2 
Gauri 2016 200 35 
NK 
NK 
Criteria 
not 
applied 
NK 
Javelle 2015 159 94 
Median 15  
6 (RA) 
40 (de 
novo RA, 
12 RF+/2 
ACPA+) 
3 (RA) 
Kularatne 2012 512 230 
7  
34 
Criteria 
not 
applied 
102 
Manimunda 2010 203 94 10 NK 34 (RF-) NK 
Miner 2015 10 8 7-10 weeks No 8 (RF-) NK 
Rosario 2015 514 344 NK NK NK NK 
Sepúlveda-Delgado 2017 10 7 NK NK None 4 
 NK – not known; UA – undifferentiated arthritis 
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Figure 2-1. Forest plot for cumulative odds ratio (95% CI) of serum IgG anti-PVB19 
antibodies in cases and controls.  
 
 
        Figure 2-2. Forest plot for cumulative odds ratio (95% CI) of serum IgG anti-PVB19 
antibodies in matched cases and controls.  
 
 
        Figure 2-3. Forest plot for cumulative odds ratio (95% CI) of serum IgM anti-PVB19 
antibodies in cases and controls.  
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 Figure 2-4. Forest plot for cumulative odds ratio (95% CI) of serum PVB19 DNA in cases 
and controls.  
 
Figure 2-5. Forest plot for cumulative odds ratio (95% CI) of serum IgG anti-EBNA in 
cases and controls.  
 
 Figure 2-6. Forest plot for cumulative odds ratio (95% CI) of serum IgG anti-EBNA in 
matched cases and controls.  
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Figure 2-7. Forest plot for cumulative odds ratio (95% CI) of serum IgG anti-VCA in cases 
and controls. 
 
 Figure 2-8. Forest plot for cumulative odds ratio (95% CI) of serum IgG anti-VCA in 
matched cases and controls.  
 
 Figure 2-9. Forest plot for cumulative odds ratio (95% CI) of serum IgG anti-EA in cases 
and controls.  
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Figure 2-10. Forest plot for cumulative odds ratio (95% CI) of serum IgG anti-EA in 
matched cases and controls.  
 
Figure 2-11. Forest plot for cumulative odds ratio (95% CI) of serum IgG anti-CMV in 
cases and controls.  
 
Figure 2-12. Forest plot for cumulative odds ratio (95% CI) of HBV in cases and controls.  
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Figure 2-13. Forest plot for cumulative odds ratio (95% CI) of HCV in cases and controls.  
         
Figure 2-14. Forest plot for cumulative odds ratio (95% CI) of serum IgG anti-VZV in 
cases and controls.  
         
Figure 2-15. Forest plot for cumulative odds ratio (95% CI) of serum IgG anti-rubella in 
cases and controls.  
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of early inflammatory arthritis with viral outbreaks such as influenza: time series analysis of the Canadian Early Inflammatory 
Arthritis Cohort. 
 
Chapter 3: Possible Association of Early Inflammatory Arthritis Onset with Viral 
Outbreaks such as Influenza: Times Series Analysis of the Canadian Early 
Inflammatory Arthritis Cohort 
 
3.1 Introduction 
Early inflammatory arthritis (IA), or undifferentiated arthritis is a recent-onset 
arthropathy with one or more swollen joints that may resolve spontaneously, develop into 
rheumatoid arthritis, another definite arthropathy or remain undifferentiated1. Rheumatoid 
arthritis (RA) is the most common IA worldwide, with a prevalence of 0.5-1% of the 
general population, and average annual incidence of 25-50 cases per 100,000 population2,3. 
In Canada, the age- and sex-standardized incidence of RA among Ontarians in 2010 was 
54 (95% confidence interval (CI) (52; 55)) cases per 100,000 population4.  
Despite the significant progress in understanding the risk factors for RA 
development, RA etiology is not fully elucidated. RA is an autoimmune disease that 
develops as a combination of immune, genetic, hormonal and environmental factors5,6. 
Among environmental factors, the role of viral infections as potential triggers of 
autoimmune diseases, particularly, inflammatory arthritis and RA7,8, is widely discussed in 
the literature. Our recent meta-analysis showed that parvovirus B19 and chronic hepatitis 
C are associated with the development of RA, and chikungunya virus is associated with 
the development of persistent IA9. 
Infections and rheumatoid arthritis 
Infections can induce or exacerbate IA via mechanisms of infection-induced 
autoimmunity, such as via molecular mimicry, bystander activation, epitope spreading and 
superantigens. Molecular mimicry implies the production of cross-reactive antibodies to 
both pathogens and self-antigens due to structural homology of the pathogens and self-
antigens10,11. Bystander activation/killing is the process of destruction of non-infected 
tissues that can operate in two ways.  The first is infection-specific T-cell production, 
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leading to the release of inflammatory substances and subsequent damage of both infected 
and healthy tissues. The second involves virus-induced activation of antigen-presenting 
cells, which in their turn activate non-specific auto-reactive T-cells12. Epitope spreading is 
a phenomenon where, similar to bystander activation, persistent infection causes activation 
of T-cells and secondary tissue destruction. As a result of continual tissue damage, peptides 
release continuously, leading to the activation of antigen-presenting cells and the spread of 
immune response from pathogen-epitope to multiple self-epitopes13. Superantigens, a 
specific type of pathogen-produced antigens that are able to stimulate a high frequency of 
T-cells, can cause a large non-specific T-cell activation and overwhelming cytokine release 
that repeatedly stimulates the immune system and autoimmune response14.  
In addition to these biological mechanisms, there is evidence, yet controversial, of 
a possible association between infections and RA from observational studies of patients 
with IA/RA. For instance, Soderlin et al. showed that 16% of early RA patients self-
reported recent infection preceding the development of arthritis15.  The case-control study 
by Sandberg et al. demonstrated that patient-reported gastrointestinal and urinary tract 
infections were associated with a significantly lower risk of incident RA, while the 
association between respiratory tract infection (sinusitis) and seronegative RA suggested a 
marginally significant risk factor (adjusted odds ratio (OR) (95% CI) = 1.31 (1.00; 1.71), 
p=0.05)16.  A systematic review and meta-analysis found no evidence to support the role 
of Epstein-Barr virus (EBV) in the development of RA17. As opposed to EBV, there was a 
higher prevalence of human parvovirus B19 (PVB19) in RA patients than controls18-20. A 
cohort study by Yaseen et al. showed that patients with recent chikungunya virus (CHIKV) 
were at a higher risk of persistent IA (adjusted OR (95% CI) = 26.75 (11.15; 64.17), 
p<0.005) on average 30 months post-infection21.  
Influenza and rheumatoid arthritis 
 Influenza is a common viral infection worldwide with usual annual epidemics 
during the late fall through early spring22. Influenza has been linked to the development of 
autoimmune disorders23-26, but its effect on the risk of IA/RA is poorly understood. For 
instance, Svec et al. in a prospective cohort study found that, among age- and sex-
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comparable subjects examined right after epidemic spread of influenza A, there was a 
significantly higher odds of being RF-positive in subjects with the presence of anti-
influenza antibodies compared to  subjects without anti-influenza antibodies (OR (95% CI) 
= 13.6 (1.4; 127.4), p=0.02)27. Giamarellos-Bourboulis et al. showed that influenza was 
accompanied by high levels of human leucocyte antigen D-related (HLA-DR) expression 
on monocytes, which is an indicator for antigen-presentation ability and T-cell activation. 
They also found a significant increase in the level of macrophage-produced pro-
inflammatory cytokines in the sera, such as interleukin-1 (IL-1), interleukin-6 (IL-6), 
tumor-necrosis factor alpha (TNF-a), in response to viral stimuli28. Alongside their 
inflammatory effects, the cytokines are able to bind to specific receptors on target cells 
(dendritic cells) and differentiate them into antigen-presenting cells, which may then 
present self-antigens for induction of specific T-cell responses. In addition, the presence of 
shared epitopes on HLA-DR molecules may increase the presentation of self-antigens by 
antigen-presenting cells, leading to rapid destruction of synovium in RA patients29.  
Thus, the similarities of the cytokines and cells involved in the pathogenesis of 
influenza and RA, coupled with the presence of rheumatoid factor-autoantibodies in 
patients with RA years before its overt clinical manifestation30-32, create a persuasive 
mechanistic explanation for the role of influenza virus exposure as a trigger of incident 
RA.  
Epidemiologic clustering and seasonality 
One of the ways we can explore the role of environmental factors, such as 
infections, in RA development is to look at the presence of disease clustering in time or 
place. However, as opposed to the studies of time-trends for infectious diseases, only a few 
studies specifically investigated time-trends in the onsets of rheumatic disorders.  For 
instance, Sonnenblick et al. with their 12 years of observations estimated the seasonality 
of giant cell arteritis onset, with the highest rates in May and June33.  Jacoby et al. described 
that, among 100 patients observed within a year of RA onset, more patient-reported RA 
onsets occurred in December through February, with December being the worst month 
with 43 onsets34. Iikuni et al. demonstrated that the season of the year may affect RA 
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activity35.  A more recent epidemiological study found no evidence to support a hypothesis 
about consistent variation of IA/RA onsets over time, with modest evidence of clustering 
in space36.  Soderlin et al. found that, among 16% of patients with early RA and self-
reported infection preceding to RA, RA onsets were more common in December through 
March. The authors suggested that the seasonality of RA onset that they observed 
corresponds with the seasonal variations of viral infections in the general population15. 
Therefore, given that studies from different countries provided similar results, we may 
suggest that RA incidence may vary throughout the year.  
Time series analysis 
Time series analysis is a method of studying associations and forecasting the data 
based on previous observations recorded at similar points in time. Time series analysis has 
been widely used by epidemiologists to examine short-term associations between 
environmental exposures and health-related outcomes37-39. Technically, time series is a 
sequence of data on exposure/outcome of interest collected at equally spaced intervals of 
time (e.g., daily, weekly, monthly)38. This method has important advantages because it 
allows both control for seasonality and long-term trends in disease variations as well as 
examination of delayed exposure effects and for confounding by time-varying factors. For 
example, Hazlett et al. applied time series analysis to show a positive association between 
daily stressors, cognitive rumination and fibromyalgia symptoms during a 35-day 
observation period40. Cordtz et al. used an interrupted time series analysis to demonstrate 
that the introduction of biological disease-modifying anti-rheumatic drugs (bDMARDs) 
was associated with a decreased incidence of total knee replacement in patients with RA41. 
Also using an interrupted time series analysis, Christie et al. reported that aquatic exercises 
significantly reduced pain, fatigue and stiffness in patients with inflammatory joint 
disorders over a 35-week period42.  
We will estimate the distribution of IA onset over time. The data from the Canadian 
Early Arthritis Cohort (CATCH) and FluWatch national influenza surveillance program 
will be combined to estimate the effect of influenza (exposure) on IA (outcome) onset, and 
examine different plausible lags (i.e. induction periods) between exposure and outcome 
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epochs. By providing evidence about a possibly causal association between influenza as an 
environmental risk factor and IA onset, our study will assist in better understanding IA 
etiology and facilitate its recognition at an early stage in the natural history.  
Objectives and Hypotheses 
Objective 1. To study the distribution of inflammatory arthritis onset over time. 
Hypothesis. We hypothesise that, being an autoimmune disease that can be 
triggered by environmental factors, more inflammatory arthritis onsets will occur 
during winter months, when peoples’ immune systems are more activated because 
of higher exposure frequency to infectious pathogens. 
Objective 2. To quantify the association between influenza and inflammatory 
arthritis onset over time.  
Hypothesis. We hypothesise that influenza as a possible environmental trigger will 
partially explain short-term variability in inflammatory arthritis onset.  
 
3.2 Methods 
3.2.1 Study Design 
The source of outcome data (IA) for the study described in this thesis is a 
prospective cohort design (CATCH), with external ecologic exposure data (influenza) 
added from a national surveillance program.  
Study methods and results are reported in accordance with Strengthening the 
Reporting of Observational Studies in Epidemiology Guidelines (STROBE)43.  
3.2.2 Setting and Source Population 
Inflammatory arthritis 
CATCH is a prospective observational cohort study that was established in 2006 to 
facilitate collaborative research and basic science within the field of early IA, and 
implement clinical knowledge translation to improve the quality of care for people with 
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IA/RA across Canada. The CATCH is an ongoing national initiative with 17 active sites 
across Canada including academic and non-academic centers located in urban, suburban 
and rural areas. Patients with recent (≤12 months) onset IA have been enrolled since 
January 2007 and followed prospectively. According to the definition of early IA, patients 
who are over 18 years old, have joint symptoms (joint pain and swelling) for 6-52 weeks, 
have ≥ 2 swollen joints or 1 swollen metacarpophalangeal (MCP) or proximal 
interphalangeal (PIP) joint, and at least 1 of the following criteria: rheumatoid factor (RF) 
≥ 20 IU, positive test for antibodies against citrullinated proteins (ACPA), morning 
stiffness ≥ 45 minutes, response to nonsteroidal anti-inflammatory drug (NSAID) therapy, 
or a painful metatarsophalangeal (MTP) joint squeeze test, are eligible for enrollment in 
the CATCH. The diagnosis of RA is based on 1987 ACR or 2010 ACR/EULAR 
classification criteria (Appendix E, Figures E-1, E-2), but patients are not required to meet 
RA criteria at baseline to be enrolled in the CATCH44,45. Patients with infectious, crystal-
induced, psoriatic arthritis or connective tissue diseases are not included in the CATCH, 
and are excluded after the enrollment if they have developed one of these diagnoses at 
follow-up46. All patients from the CATCH receive treatment according to the Canadian 
guidelines for RA management47,48. 
Eligible patients referred to rheumatologists by primary care physicians receive an 
offer to participate in the CATCH. Before enrollment, patients provide voluntary, written 
informed consent to give demographic, clinical and laboratory data. The CATCH study 
was approved by the research ethics boards of participating institutions.  
Patients are recruited in the CATCH and followed prospectively every 3 months for 
the first year, and every 6 months thereafter using a standardized protocol. The study 
protocol includes patient- and physician-reported data collection, as well as routine 
laboratory tests (Appendix E, Figure E-3).  
The data collection in the CATCH is performed by trained rheumatologists and/or 
coordinators.  All the data are entered into an encrypted, password-protected computer, and 
anonymized and synchronized to a central server. The central database follows the 
Canadian Standards Association Privacy Code principles. All the data are stored in SAS 
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files for further analyses. 
Influenza  
According to the Center for Disease Control and Prevention (CDC), influenza (flu) is a 
contagious respiratory illness caused by influenza viruses affecting upper and sometimes 
lower respiratory tracts. Currently, there are three main types of influenza – influenza A 
H1N1, A H3N2 and B. Influenza symptoms may vary, but usually include fatigue, fever, 
cough, sore throat, headaches, runny or stuffy nose, and muscle or body aches. Laboratory 
confirmation of influenza cases is based on the presence of viral culture, direct/indirect 
fluorescent antibody assay (DFA/IFA), reverse transcription polymerase chain reaction 
(RT-PCR), or a rapid influenza diagnostic test (RIDIT)49. 
3.2.3 Study Population 
Inflammatory arthritis/Rheumatoid arthritis 
 A subset of patients was identified in the CATCH database according to the 
following inclusion and exclusion criteria: 
Inclusion criteria 
a. Age  18 years 
b. Early inflammatory arthritis or early rheumatoid arthritis 
c. Symptom duration 12 months from baseline date 
d. Patients enrolled from January 2007 through January 2017 
Exclusion criteria 
a. Presence of another confirmed rheumatic disease at baseline 
b. Absence of measured patient- and physician reported date of IA symptom onset 
The timeframe for this study has been set according to the beginning of the recruitment 
in the CATCH, and the cut-off date for data collection for the current analysis. No 
limitations were placed on the provinces or sites across Canada where patients were 
recruited. No additional ethical approval was required for this study to analyze the data 
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from the CATCH. 
Influenza 
We obtained monthly laboratory confirmed influenza counts from September 2010 
to December 2016 inclusively in each province from the FluWatch 
(https://www.canada.ca/en/services/health/diseases-conditions.html). The timeframe for 
the data retrieval has been set to enable the correspondence of IA onset with influenza onset 
over time.  
3.2.4 Data Measurements 
Outcome variable 
 The main outcome of our study was monthly number of early incident IA.  In many 
cases the onset of IA is insidious, resulting in a several month delay before the patient is 
diagnosed50. Therefore, for this analysis we used the date of first symptom onset to estimate 
the monthly number of early IA onsets. To do this, we used two sources of information 
from the CATCH. The first source was a patient-reported date of symptom onset.  Patients 
at baseline were given the questionnaire where they were asked to answer the following 
question: “When did you have your first episode of joint pain and swelling lasting for at 
least 6 weeks?” The second source was physician-reported date of symptom onset.  This 
information was collected by participating rheumatologists, who asked each patient at their 
baseline visit about the date of symptom onset, the onset being defined as a first episode of 
joint pain and swelling lasting longer than 6 weeks. Both patient- and physician-reported 
dates of symptom onset were recorded in a month/year format. Since we allowed a 
maximum time-lag of 12 months for symptom onset before enrollment in the CATCH, the 
IA onset could happen from 1 January 2006 to 31 January 2016.  For the purposes of the 
time series regression analysis, we included IA onsets recorded from September 2010 to 
December 2016 inclusively. The number of IA onsets was obtained as monthly cumulative 
values and were treated as count data.  
Diagnosis of RA was a binary variable (yes/no) and was reported by physicians 
based on the scoring-based algorithm used to determine whether a patient meets the 1987 
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ACR and 2010 ACR/EULAR RA classification criteria. We defined a patient as having 
RA if the answer to either of RA classification criteria at baseline visit was ‘yes’.  
The number of tender (n=28) and swollen (n=28) joints was recorded by a physician 
and was considered as a count variable.  
Physicians assessed patients’ disease activity using the Disease Activity Score 
(DAS28). DAS28 is a 3-variable score that uses tender 28 joint count, swollen 28 joint 
count, and erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) to calculate 
the disease activity51,52. (Appendix E, Figure E-4 for formula and description). The level 
of RA activity can be interpreted as low (2.6 ≤ DAS28 ≤ 3.2), moderate (3.2 < DAS28 ≤ 
5.1), or high (DAS28 >5.1). A DAS28 <2.6 corresponds with being in remission according 
to the ACR criteria53. DAS28 score was considered as a categorical variable. 
At each visit, patients completed a validated measure of RA symptoms and 
function, such as Health Assessment Questionnaire-Disability Index (HAQ DI)54 
(Appendix E, Figure E-5 for HAQ-DI description). HAQ DI score was considered as a 
count variable.  
The presence of autoantibodies such as RF and ACPA was a binary (yes/no) 
variable. The autoantibodies’ status was defined based on the information either from 
previous testing performed in outpatient commercial laboratories, or from testing at the 
CATCH site.  
Primary exposure variable 
In September 2010, the Public Health Agency of Canada launched a new national 
management and surveillance report system FluWatch in order to improve the monitoring 
of influenza and influenza-like illnesses across Canada. The FluWatch has several data 
sources monitoring influenza and influenza-like illnesses, such as laboratories, hospitals, 
doctor’s offices and provincial and territorial ministries of health. The FluWatch identifies 
influenza cases by reviewing hospital, laboratory and admission databases and infection 
control logs for patients hospitalized during influenza season with a documented positive 
influenza test.  All the data on influenza activity across Canada are publicly available and 
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can be accessed on the website https://www.canada.ca/en/services/health/diseases-
conditions.html.  For the purposes of the current study, we used only laboratory confirmed 
new influenza A and B cases to obtain the influenza time series. Influenza counts were 
retrieved from the FluWatch database and recorded as monthly total frequencies.  
We included in the analysis influenza cases recorded from September 2010 to 
December 2016 inclusively to study the association between IA and influenza time series. 
The monthly influenza onsets were treated as count data.  
Covariates and confounders 
Sociodemographic variables 
Patients enrolled in the CATCH reported their age, sex, ethnicity, education and 
smoking status. The age of patients at enrollment in the CATCH was recorded at baseline 
to the nearest year. Ethnicity was a categorical variable with eight following categories: 0 
– Caucasian; 1 – Hispanic; 2 – African Canadian; 3 – Native Canadian; 4 – European; 5 – 
South Asian/Indian; 6 – East Asian/Oriental; 7 – other. Education was an ordinal variable 
with seven following categories: 0 – elementary school; 1 – high school; 2 – college/trade 
school; 3 – University Bachelor; 4 – Masters; 5 – PhD; 6 – other. Smoking status was a 
categorical variable with three following categories: 0 – never smoker; 1 – current smoker; 
2 – ex-smoker.   
Confounders 
 Since the main unit of our analysis is the month of disease onset, not the individual 
person, common risk factors (e.g., age, sex, education) that are unlikely to change from 
month to month at the population level are not necessary to include as confounders. We 
could not identify in the CATCH and FluWatch potential confounding variables that could 
probably be associated with monthly changes in the IA and influenza onset.  
3.2.5 Statistical Analysis 
Statistical analysis was performed using SAS 9.4 and StataSE 1355,56 statistical 
software. All results were reported at a two-sided level of significance of 0.05, and 95% 
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confidence intervals were provided. We used unpaired two-sample t-tests to compare 
continuous variables, and Pearson 2 tests of independence for categorical variables. 
Fisher’s exact tests were used instead of 2 tests of independence when an expected 
frequency in a response category was less than 5. 
Sample characteristics 
Descriptive statistics were computed for patient sociodemographic and medical 
characteristics for the IA group as a whole, and for two subgroups of patients with RA and 
undifferentiated inflammatory arthritis (UIA). We calculated mean  standard deviation 
(SD) or median (interquartile range) for count and continuous variables, and frequencies 
and percentages for categorical variables.  
For disease-specific characteristics, we imputed missing baseline data only for the 
variable ‘diagnosis of RA’ (n=47), where we used the information about diagnosis from 
the next follow-up visit 3 months after the baseline visit. For other disease-specific 
variables and sociodemographic characteristics, we did not impute missing data and 
presented only available data on patients.  
We used intraclass correlation coefficients (ICC) to measure the degree of 
correlation and agreement between patient and physician-reported date of symptom onset 
(interrater reliability)57. A two-way mixed-effects analysis of variance (ANOVA) model 
was used to test the reliability between study-specific raters. We pre-specified the 
minimum ICC with no less than moderate reliability (ICC=0.60-0.74) that allowed us to 
use only patient-reported date of symptom onset to measure the number of IA onsets over 
time58. 
Objective 1: To describe the distribution of early incident inflammatory arthritis over time. 
We assessed the monthly distribution of IA onset from January 2006 to January 
2016 visually (box plots) and statistically (ANOVA). We plotted ten-year aggregated by 
month IA onset. Summary statistics using mean values and 95% CI were reported. One-
way ANOVA was used to perform an overall comparison in the number of IA onsets over 
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12 months. In order to compare IA seasonal frequencies, two groups based on winter and 
all other seasons of the year were created, and corresponding ten-year average cumulative 
IA frequencies were compared between the winter and all other seasons using two-sample 
t-test. 
Objective 2: To quantify the association between influenza and inflammatory arthritis over 
time. 
Two univariate time series were obtained: monthly influenza time series and monthly 
IA time series from September 2010 to December 2016 inclusively.  Descriptive statistics 
including mean values and 95% CI were presented.   
The association between the two time series was assessed using cross-correlations and 
time series regression analysis.  
Cross-correlations with lagged values 
Temporal relationships between influenza and IA time series were assessed with cross-
correlations59. The cross-correlation method is based on identifying lags of the input series 
x at time t (influenza) that can be predictive of the response series y at time t (IA). 
Therefore, a sample cross-correlation function (CCF) is the set of correlations between xt+h 
and yt for h=0, ± 1, ±  2.. ± n. In the case when xt+h with negative h is a predictor of yt, it is 
said that x leads y.  In cases when xt+h with positive h is a predictor of yt, it is said that x 
lags y. Maximum number of 12 of lags for influenza (1 lag = 1 month based on our data) 
that might be predictors of IA were included. As we were interested in whether influenza 
leads IA, we reported correlation coefficients only for negative lags.  
Time series regression analysis of inflammatory arthritis and influenza 
We investigated whether the short-term variation in the IA onset can be partially 
explained by changes in the influenza onset over time using Poisson regression for count 
data.  Poisson regression assumptions were checked. We followed the method described 
by Bhaskaran et al.38 to remove seasonal and long-term patterns in the data. First, we fit 
cubic splines function of time by using smoothly joined polynomial curves for the whole 
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study period. There is no single rule for how many knots to use. For daily time series data, 
it is recommended to use 6 knots per year ((number of calendar years * 7)-1)60. We used 
equally spaced knots (reference points) to fit the spline function to the IA time series and 
allow the appropriate control for seasonality. Akaike information criterion (AIC) and p-
values were used to assess how the splines fit the data61. The model with the minimum AIC 
based on different number of knots was chosen. The number of knots used to fit the data 
was 15-25. The raw IA time series and fitted-with-splines model were plotted over time 
using scatter plots. The residuals from the fitted model (after control for seasonality) were 
assessed with the scatter plot. Second, we modelled the influenza-inflammatory arthritis 
association with 0 lag using Poisson regression (and adjusted standard errors to account for 
over-dispersion) and adjustment for seasonality and long-term trends. We also estimated 
whether the lagged by 1 and 3 months values of influenza were associated with IA onset. 
Estimated incidence rate ratio (IRR) with 95% CI and p-values were reported. 
3.3 Results 
3.3.1 Baseline Sample Characteristics 
At the time of data extraction (12 October 2017), 2774 patients with early IA met 
our eligibility criteria. After we excluded patients with  13 months patient-reported 
symptom onset, 2519 patients constituted the final analytic sample. Among them, 87.7% 
(n=2209) fulfilled either 1987 ACR or 2010 EULAR/ACR RA classification criteria, and 
12.3% (n=310) had UIA. Baseline characteristics of patients are provided in Table 1 
(Appendix E, Table E-1). The majority of patients enrolled in the CATCH were from 
Ontario (44.7%) and Quebec (36.1%). The majority of patients with IA were female 
(71.1%), of Caucasian ethnicity (81.5%), and never smokers (44.2%), with a mean age of 
54.715.1 years. No statistically significant differences in these variables were found 
between patients with confirmed RA and UIA. Approximately 42% of IA patients had <= 
high school education, and patients with UIA were more likely to have higher than high 
school education compared to RA patients (p=0.004).   
 RA patients were consistently different than patients with UIA on all eleven disease 
characteristics, although not all parameters reached statistical significance. Patient-
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reported symptom duration from the baseline visit was on average 5.43.1 months, with 
no statistically significant difference between patients with RA and UIA (p=0.06). 
Physician-reported symptom duration was 5.33.0 months, with no difference between 
patients with RA and UIA (p=0.09). Patients with IA had on average 8.07 tender 28 joint 
count, and RA patients had significantly more tender joints compared to UIA patients (97 
vs 33, p<0.0001). Patients with IA had 76.0 swollen 28 joint count, and a significantly 
higher number of swollen joints were in patients with RA compared to UIA patients (86 
vs 33, p<0.0001). Baseline disease activity based on DAS28 (CRP) 3-variable was 
4.61.3 in all IA patients, and was significantly higher in RA compared to UIA patients 
(4.71.3 vs 3.51.0, p<0.0001). Similarly, DAS28 (ESR) 3-variable was 4.91.5 in all IA 
patients, and was significantly higher in RA compared to UIA patients (5.11.4 vs 3.71.2, 
p<0.0001). Patients with IA had ESR of 27.022.6 mm/h, and CRP of 14.418.4 mg/l. 
Patients with RA had significantly higher levels of ESR and CRP than UIA patients 
(27.922.9 vs 20.518.8 mm/h, and 15.118.9 vs 8.812.6 mg/l, for ESR and CRP, 
respectively; p<0.0001 for both comparisons). HAQ DI score in IA patients was on average 
1.00.7, and was significantly higher in RA than UIA patients (1.10.7 vs 0.70.6, 
p<0.0001). We found that 44% and 52.7% of IA patients were RF- and ACPA-positive, 
respectively. However, there were n=12 (0.5%) missing data for RF-status and n=702 
(28%) for ACPA-status. Patients with RA were significantly more often RF- and ACPA-
positive compared to UIA patients (47.9% vs 11.1%, and 57.5% vs 14.9%, for RF and 
ACPA, respectively; p<0.0001 for both comparisons).  
3.3.2 Univariate Analysis of Inflammatory Arthritis Time Series 
We found moderate agreement between patient-reported and physician-reported 
date of symptom onset (ICC (95% CI) = 0.70 (0.67; 0.79)). Therefore, the patient-reported 
date of symptom onset was used as a basis for IA time series calculations. In addition, we 
did not differentiate between RA and UIA patients for subsequent analyses since the 
majority (87.7%) of IA patients had confirmed RA.  Overall these observations support the 
interpretation that most patients accurately date symptoms that are subsequently 
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diagnostically confirmed, and that in many cases UIA and RA represent different stages in 
the natural history of the same disease.    
We assessed the number of IA onsets aggregated by month visually (box plots) and 
quantitatively for the entire study period (Figure 3-1). On average, there were 19 ± 9 SD 
monthly onsets of IA from January 2006 to December 2016. The number of IA onsets for 
ten-year aggregated data varied, being on average 27 (95% CI (19; 34)) in January, 19 
(95% CI (13; 24)) in February, 20 (95% CI (15; 25)) in March, 16 (95% CI (12; 20)) in 
April, 19 (95% CI (14; 23)) in May, 18 (95% CI (13; 23)) in June, 15 (95% CI (12; 19)) in 
July, 18 (95% CI (12; 25)) in August, 18 (95% CI (11; 24)) in September, 21 (95% CI (16; 
26)) in October, 19 (95% CI (14; 25)) in November and 20 (95% CI (13; 26)) in December. 
Although most IA cases occurred in January, the overall difference in the monthly average 
onsets was not significant (p=0.6).   
The number of IA onsets aggregated by season was assessed visually (box plots) 
and quantitatively (Figure 3-2). From the figure, we can see that monthly average IA onsets 
were more common in winter compared to other seasons (mean 22 (95% CI (18; 25)) and 
18 (95% CI (17; 20)), respectively, p=0.03).  
3.3.3 Bivariate Time Series Analysis of Inflammatory Arthritis and Influenza 
Descriptive analysis 
Two univariate time series for IA and influenza were analyzed from September 
2010 to December 2016. Figure 3-3 shows linear plots of the IA and influenza counts over 
time for the whole study period. From the Figure, we can see recurring high-level patterns 
in the number of influenza onsets during early winter months for the entire study period. 
IA onsets tend to have noticeable high peaks in January and low peaks in summer. 
However, there were occasional, comparable to January, high-level patterns in August 
2014. There is also a downward trend in the IA time series at the end of the study period. 
This trend was an artefact of the decrease in the enrollment activity in the CATCH, not a 
real trend in incidence. 
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For the 6-year study period, there was on average 18 (95% CI (17; 19)) IA onsets 
and 2073 (95% CI (2062; 2083)) influenza onsets.  
Cross-correlations with lagged values 
Cross-correlations for IA and influenza time series are presented in Figure 3-4. As 
we can see, there were weak positive correlations when influenza led IA by 7 lags (r=0.2) 
and zero lags (r=0.11). However, all the coefficients were very tight around the null value 
(i.e. zero), and shifts in influenza time series did not affect the correlation coefficients 
substantially.  
Time series regression analysis of inflammatory arthritis and influenza 
Time series regression analyses which are unadjusted for seasonal and long-term 
patterns may risk spurious conclusions. Therefore, we applied the flexible spline function 
of time fitted to the IA time series to remove these patterns from our data (Figure 3-5). As 
we can see from the figure, the model with splines does not reveal any seasonal pattern or 
trend over time, as also illustrated in the Figure 3-3.  
According to the output from Poisson regression of IA time series on splines, all 
the estimated coefficients are significantly more than zero and have precise 95% 
confidence bands. The lowest AIC was when we used 18 knots (6.52). These parameters 
confirm that the linear combination modelled the seasonal pattern in the outcome as close 
as possible. From the plot of residuals in Figure 3-6 we can see that the residual variation 
in monthly IA onsets after control for seasonality and trend is no longer present, though 
some outliers can be identified. 
Poisson regression of the IA time series on the influenza time series with adjustment 
for seasonality and trend resulted in the incidence rate ratio of 1.00003 (95% CI) 
(1.000005; 1.000053), p=0.02). This means that every additional influenza onset is 
associated with on average 0.003% increase in the IA onset, or every 100 influenza cases 
are associated with on average 0.3% increase in the IA onset.  
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We estimated that, for the lagged by 1 and 3 month values of influenza, the 
estimated effect of influenza on IA onset was not significant (0.99 (95% CI (0.99; 1.00), 
p=0.84), and 0.99 (95% CI (0.99; 1.00), p=0.33)), respectively.  
 
3.4 Discussion 
Our time series analysis is to our knowledge the first to assess the monthly and 
seasonal distribution of early incident IA onsets over ten years, and to quantify its possible 
association with influenza.  
The etiology of any disease should be explored using incident cases from the general 
population in order to get unbiased estimates. The IA time series for our study was retrieved 
from the CATCH, a large Canadian prospective cohort study of adults with early incident 
IA.  Participation in the study is voluntary, thus we were unable to estimate the true number 
of IA onsets for the study period. However, the CATCH is an inception cohort where only 
patients with new-onset of IA across Canada are enrolled. Moreover, we found that our IA 
cohort had similar age, sex, symptom duration and disease characteristics as patients in the 
UK Norfolk Arthritis inception population-based cohort of patients with early 
inflammatory polyarthritis62.  
We did not separate RA and UIA patients for the purpose of analyses of disease 
variability over time and its possible association with influenza for several reasons. First, 
our study showed that RA constituted the major subset of patients with IA. Second, at early 
stages, it can be hard to differentiate RA from the broader IA group63. Lastly, in our 
analysis we used only the baseline information on the diagnosis. It is possible that patients 
with UIA at baseline started satisfying one of the RA classification criteria at follow-up 
visits. It may therefore may be useful to study the disease characteristics and patterns in IA 
group as a whole. 
We used the patient-reported date of symptom onset as a proxy measure of IA onset 
in our study. In case of symptomatic disease with gradual onset such as IA, that takes time 
for the full expression of signs and symptoms required for confirmatory diagnosis, a 
patient’s recall onset might be closer to ‘the truth’ than a physician’s. The CATCH 
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questionnaire used an explicitly defined question describing the symptom onset as a first 
episode of joint pain and swelling lasting for at least 6 weeks. Also, the inclusion of we 
only patients with recent (≤ 12 months) IA onset that, compared to longer history, may 
have increased the accuracy of patients’ recall of their symptoms onset. Moreover, we 
estimated moderate reliability between the patient- and physician-reported date of 
symptom onset. Similarly, Silman et al. used patient-reported symptom onset to analyze 
possible clustering of early IA cases in time or place36. Sandberg et al. used patient-reported 
data about infections occurring 12-24 months prior to RA to estimate the relationship 
between infections and the risk of RA. They emphasized that the timing of infections’ 
history was the major strength of their study16. Soderlin et al. used patient-reported 
information to estimate the association between early RA and preceding infections15. 
Vandenbroucke et al. in their study of the frequency of patient-reported infections among 
patients with RA emphasized that RA patients tend to be more pre-occupied with their 
health conditions, therefore the recall bias may have only increased the incidence of 
infections and strengthen the validity of negative results64.  
Studies about seasonal variability of IA/RA onset are scarce. There is some evidence 
that the lack of sunshine and light may exacerbate disease activity in patients with RA35,65. 
Jacoby et al. reported that more RA onset occurred in December through February, with 
December being the worst34. Similarly, Soderlin et al. observed that, in RA patients with 
self-reported preceding infections, more RA onset occurred in December through March, 
compared to other months15. Silman et al. in their time series analysis found inconsistent 
peaks of incident IA in April and October during two years of observations36. We estimated 
that more IA onsets occurred in winter and, more specifically, in January, though p-values 
for the comparisons between months were not significant. However, according to 
Goodman S., when we compare the groups, it is not only about p-values, but also about the 
direction and magnitude of the estimated effect66. Our results showed that average IA 
onsets in winter were significantly higher than in other seasons, and that 95% CI around 
these values had the same direction, were consistent and precise. 
We assessed the bivariate distribution of IA and influenza and found similar high-
level patterns in January over the six-year study period. Cross-correlation analysis showed 
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weak positive correlations between IA and influenza at 0 lag and when influenza led the 
IA onset by 7 lags (months). We estimated the effect of influenza on IA using regression 
analysis. As we were interested in modelling the short-term association, we used smoothing 
methods to adjust for seasonal and long-term trends in the raw data that might obscure the 
true exposure-outcome relationship. We estimated that if there is an attributable risk of IA 
due to influenza, it is very small (0.003%). However, if the relationship is causal, there 
would be on extra 0.3% of IA per 100 cases of influenza.  
It is thought that simple cross-correlations can overestimate the putative exposure-
outcome association67. However, because it is known that infections can trigger an 
autoimmune response, it is highly plausible that influenza could lead the IA onset by 
several months via the mechanisms of infection-induced autoimmunity such as molecular 
mimicry, and autoantibodies (RF, ACPA) formation. There is an evidence that RF-and 
ACPA-antibodies can be present in patients with RA in the years before they develop 
clinical symptoms of RA68. Svec et al. in their prospective cohort study of individuals 
before and 1 month after the influenza outbreak showed that the age- and sex-adjusted odds 
of being RF-positive were significantly higher among individuals with anti-influenza 
antibodies compared to those with no anti-influenza antibodies27. Prospective studies at the 
individual level are required to estimate whether influenza is a risk factor for IA/RA.  
 
3.5 Conclusions 
Environmental risk factors could explain up to 34% of RA etiology68. We found that 
early inflammatory arthritis onsets tend to cluster in winter months, when the immune 
system is exposed to more infections. We found that if the association is causal, the 
attributable risk of inflammatory arthritis due to influenza is very small. More studies are 
required to specifically explore the effect of influenza as well as other infections and 
environmental factors on the risk of early inflammatory arthritis.  
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Figure 3-1. Inflammatory arthritis onset aggregated by month, 2006-2016. 
 
Figure 3-2. Inflammatory arthritis onset aggregated by season, 2006-2016. 
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Figure 3-3. The number of inflammatory arthritis (top panel) and influenza 
(bottom panel) onsets over time, 2010-2016. 
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Figure 3-4. Cross-correlations of inflammatory arthritis and influenza time series. 
 
            
Figure 3-5. Flexible spline function of modelling seasonality and trends in the 
inflammatory arthritis time series, 2010-2016. 
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Figure 3-6. Residual variation in monthly inflammatory arthritis after control for 
seasonality and trends. 
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Chapter 4: Summary and Discussion 
4.1 Introduction 
 The overall goal of this research was to improve RA recognition at early stages by 
better understanding the viral etiology of rheumatoid arthritis (RA), and creating a 
scientific platform for future studies to specifically explore the role of different putative 
viruses in the development of RA. 
Our research suggests that there is an increased risk of RA or persistent 
inflammatory arthritis (IA) after human parvovirus B19 (PVB19) and chikungunya virus 
(CHIKV). There seem to be a risk of RA after HCV infections, but whether it is a true RA 
or HCV-associated arthritis is not clear. Also, we found clustering of IA onset in winter 
compared to other seasons. Time series analysis showed that there is a very weak 
association, and therefore a small potential causal effect of influenza on IA.   
This chapter summarizes the findings of our research and discusses it within the 
context of previous literature. Also, it outlines the strengths and weaknesses and potential 
implications, and suggests future research directions.  
4.2 Summary of Key Findings 
4.2.1 A Systematic Review and Meta-analysis of Viral Exposures as a Risk for 
Rheumatoid Arthritis 
 Associations between viral infections and the risk of RA have been widely 
discussed in the literature. Though viruses such as PVB19, EBV and CMV were considered 
as well-known risk factors for RA, we found that individual studies that explored these 
associations had controversial results.  This research is the first systematic review and 
meta-analysis on the presence of serological markers of different putative viral infections 
in patients with RA versus healthy individuals.  
Among 6724 citations screened, 318 articles were eligible for full text review using 
inclusion and exclusion criteria. Final analytical sample included 78 full texts, 48 of which 
were included in the meta-analysis. Among included studies, the majority were case-
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control studies (n=62). Sample sizes differed across the studies, but we specified the 
minimum sample size of ten for cases and controls as an inclusion criterion. We found that 
half of the studies had poor quality due to weak external validity, internal validity (control 
over confounding), and power/sample size calculations. With respect to outcome and 
exposure measurement as sources of heterogeneity, among cases, all patients were adults, 
predominantly females, who satisfied RA classification criteria. The majority of the studies 
used 1987 ACR classification criteria1, but there were studies who applied other RA criteria 
(ACR 1958, ACR/EULAR 2010), or did not report/specify RA classification criteria in 
their research (n=15). Control groups were represented by healthy adults or subjects with 
osteoarthritis or trauma, and were mostly females. Viral exposures were estimated based 
on the presence of immunoglobulin (Ig) G, M antibodies to viruses in sera, and on viral 
deoxyribonucleic acid (DNA) isolation from sera. Among case-control studies, only 25% 
reported cut-off levels of seropositivity for viral antibodies, and these cut-off levels varied 
across the studies. Regarding control over known confounders, only eighteen studies used 
matching of cases with controls, four of which matched for age only.  
 Our research found a significant association between RA and serological markers of 
PVB19 infection such as anti-PVB19 IgG and PVB19 DNA (OR (95%CI = 1.76 (1.09; 
2.84), p=0.02 and OR (95% CI) = 3.53 (1.00; 12.53), p=0.05, respectively). The association 
still remained significant after subgroup analysis of studies that matched cases and controls 
for age was performed (OR (95% CI) = 2.22 (1.04; 4.75), p=0.04 for anti-PVB19 IgG). 
Although there was a considerable heterogeneity in the estimated effect, the results from 
individual studies had the same direction and precise confidence intervals. Only one study 
produced a wide confidence interval, where cases outnumbered controls by a 3:1 ratio 
which could possibly explain such imprecision of the estimated effect2.  
No significant association was found between RA and the presence of IgG antibodies 
to Epstein-Barr nuclear antigens (EBNA) (OR (95% CI) = 1.05 (0.79; 1.39), p=0.75). 
Subgroup analysis of studies that matched cases and controls for age also resulted non-
significant odds of the presence of anti-EBNA IgG in RA compared to controls (OR (95% 
CI) = 1.04 (0.7; 1.54), p=0.84). Both estimated results had very low heterogeneity, and 
precise and consistent confidence intervals. As opposed to the IgG anti-EBNA, we found 
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significant odds of the presence of antibodies to viral capsid antigens (VCA) in RA patients 
compared to controls (OR (95% CI) = 1.5 (1.07; 2.10), p=0.02), with low heterogeneity. 
However, the association became not significant when we restricted the analysis to studies 
that matched cases and controls for age (OR (95% CI) = 1.20 (0.35; 4.12), p=0.77). We 
found a significant association between the presence of antibodies to early antigens (EA) 
and RA, and the association remained significant when the analysis was restricted to 
matched cases and controls (OR (95% CI) = 2.74 (1.27: 5.94), p=0.01, and OR (95%CI) = 
7.38 (1.33; 40.94), p=0.02, respectively). However, this analysis was based on small 
number of studies, compared to studies that measured IgG EBNA and IgG VCA antibodies. 
Also, the results were highly heterogeneous and had wide confidence intervals, and 
therefore may not be valid enough to make definite conclusion about the association 
between the presence of EA anti-EBV antibodies and the risk of RA. Our results are similar 
to the results of Ball et al., who in their systematic review found no association between 
Epstein-Barr virus (EBV) seroprevalence and RA3.  
We found not significant odds of the presence of IgG antibodies to cytomegalovirus 
(CMV) in RA patients compared to controls when all cases and controls were analyzed, 
and in subgroup analysis restricted to matched cases and controls for age (OR (95% CI) = 
1.19 (0.79; 1.78), p=0.42 and OR (95% CI) = 1.61 (0.73; 3.55), p=0.24, respectively). The 
results had high heterogeneity, but precise and consistent confidence intervals. Only one 
of the studies included in meta-analysis showed a significant association between CMV 
and RA, but this study had very poor quality, and therefore may have produced invalid 
results.  
We failed to find evidence of increased risk of RA after chronic hepatitis B (HBV) in 
case-control studies (OR (95% CI) = 1.37 (0.83; 2.25), p=0.22). However, only five 
studies, none with matching, contributed to the pooled result, producing high heterogeneity 
and imprecise confidence intervals. Also, one study reported substantially lower 
prevalence of antibodies to hepatitis B antigens (HBAg) in both cases and controls than the 
other studies which suggests possible sampling bias4. After we reread the article, no 
apparent cause for the low exposure prevalence was identified. However, we suggest 
possible problems in performance of laboratory tests that resulted in implausibly low rates 
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of antibody detection. One methodologically strong cohort study estimated that, adjusted 
for potential confounders, short-term risk of RA development was comparable between 
patients with HBV infection and HBV-free individuals (hazard ratio (HR) (95% CI) = 1.09 
(0.74; 1.63), p>0.05)5. Therefore, we may suggest that there is no increased risk of RA 
after HBV.  
On the contrary, case-control studies demonstrated that patients with chronic hepatitis 
C (HCV) had almost 3-times higher odds of RA compared to healthy individuals (OR (95% 
CI) = 2.82 (1.35; 5.90), p=0.006). The results of a cohort study also found that patients 
with HCV have higher risk of RA development compared to HCV-free individuals 
(adjusted HR (95% CI) = 2.03 (1.27; 3.22), p<0.01). Moreover, the same cohort study 
found that patients with coincident HCV and HBV infection have marginally significant 
risk of RA development (adjusted HR (95%CI) =1.92 (0.94, 3.92), p>0.05)5.  
We found evidence that there may be a risk of persistent IA and RA after CHIKV, a 
recently discovered viral infection. Among studies that were identified, the majority were 
case-series and only three were cross-sectional or cohort. Case-series studies showed that 
CHIKV can lead to persistent IA or rheumatoid factor (RF) – negative RA. However, some 
studies did not report sample sizes, previous history of joint disorders, or RA classification 
criteria that they applied. Also, follow-up periods differed between studies, from seven 
weeks up to ten months. In addition, case-series studies are prone to biases due to lack of 
concurrent control groups, and therefore may not truly reflect the association between 
CHIKV and the risk of IA/RA in the population. However, one cross-sectional study 
showed that 60% of CHIKV-positive individuals developed persistent, mostly RF-negative 
IA6. The second cross-sectional study estimated that 20% of CHIKV-positive subjects 
developed persistent IA, whereas 6% had confirmed RA. They also found that age and 
symmetrical arthritis at baseline were significantly associated with the development of RA 
at follow-up7. Similarly, a cohort study found that CHIKV-positive patients were at 
significant risk of persistent IA compared to CHIKV-negative individuals (adjusted OR 
(95% CI) = 26.75 (11.15; 64.17), p<0.005). Given these study results, it seems there is a 
risk of IA after CHIKV. However, there could be misclassification of chronic viral/post 
viral arthritis and actual, more destructive RA, therefore more studies with longer follow-
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up are required to estimate the risk of RA after CHIKV. 
There were some other viral infections reported as potential risk factors of RA, such as 
herpes, varicella, measles and influenza, but due to small number of studies that explored 
these associations, the results could not be summarized and did not allow us to make 
definite conclusions.  
4.2.2 Possible Association of Early Inflammatory Arthritis Onset with Viral Outbreaks 
such as Influenza: Times Series Analysis of the Canadian Early Inflammatory Arthritis 
Cohort 
The presence of disease clustering in time or place suggests an environmental 
cause. RA is an autoimmune disease that can be triggered by environmental factors such 
as viral infections. Putative viral infections can also cluster.  Using time series analysis, 
this research investigated the distribution of early incident IA (including confirmed RA 
and undifferentiated IA) over time, and estimated the effect of influenza on IA onset. We 
used patient-reported date of first symptom onset as a proxy measure of IA onset. Although 
patient-reported outcomes are prone to biases, a moderate agreement between patient- and 
physician-reported date of symptom onset justified the use of the former parameter in our 
analyses. The vast majority of patients with early IA had confirmed RA (88%), therefore 
we analyzed the IA group as a whole. We found that significantly more IA onset occurred 
in winter compared to other seasons. This observation goes on par with the two earlier 
studies, where December through March were reported as months with the highest number 
of RA onset8,9.  
Bivariate analysis of IA and influenza revealed similar peaks of both diseases in 
January. However, we did not find substantial cross-correlations between IA and influenza 
onset over time. We found a risk, although very small, of IA onset due to influenza over 
time. The literature search could not reveal any information with regards to the risk of 
IA/RA after influenza. However, given the plausibility of influenza virus trigger RA, our 
study results are valid.   
4.3 Potential Implications 
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 RA is an autoimmune disease with a complex etiology, where environmental 
factors can have up to 34% attributable risk10. The overall findings of this research confirm 
that PVB19, HCV and CHIKV can be considered as potential risk factors of IA/RA. Our 
study provides novel data about the risk, although very low, of IA after influenza.  
The fact that we found clustering of IA onsets in winter may suggest that it is 
associated with the lower defense capabilities of the immune system during winter 
compared to other seasons. Another possible explanation is that winter weather has an 
effect on symptom awareness or expression in patients, leading to an apparent increase in 
incidence due to the time of the year patients seek care. We assume that it would be 
important for physicians to be aware of possible associations between above mentioned 
viruses and RA at the time when they first see a patient with joint pain and swelling lasting 
for at least 6 weeks, and to schedule appropriate and timely follow-up visits that would 
allow to elucidate the diagnosis of RA and start the appropriate treatment as early as 
possible. Recent studies demonstrated that the earlier and more adequately RA is treated, 
the better prognosis a patient has11–13. It is therefore crucial to recognize RA at early stages 
to prevent severe joint destruction and improve patients’ prognosis.  
It is also hoped that we created a scientific platform for future studies to specifically 
explore the role of viral infections in the development of RA using observational study 
designs with rigorous quality.  
4.4 Study Strengths 
 There are several strengths of this thesis that enabled us to expand on previous 
research about the viral risk factors of RA. The strengths of our systematic review and 
meta-analysis are three-fold. First, it was based on a comprehensive literature search, where 
results were reported in accordance with PRISMA guidelines, and all subgroup analyses 
were pre-specified to ensure methodological rigor. Second, we assessed the quality of 
included studies using the quality assessment tool specifically modified for observational 
studies, and reported the results with high accuracy and precision. Third, this systematic 
review and meta-analysis was the first to analyze the association between all potential viral 
exposures and RA development.  Articles were collected using five databases and abstract 
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archives from two major rheumatology conferences using thorough search strategy created 
with the help of a medical research librarian.  We believe we were able to obtain all relevant 
articles by following strictly specified inclusion and exclusion criteria. Given that this 
review was conducted with rigorous methodology, we suggest it would add clarity to the 
existent research on the topic.  
 There are several strengths of the time series analysis of IA and influenza onset. 
First, our research is based on a large sample of patients with new-onset IA from a 
multicenter Canadian inception IA cohort with standardized case ascertainment, where all 
clinically relevant information was available in the database. This increases the internal 
generalizability of the study results. Second, the fact that we included patients with recent 
onset IA (≤ 12 months), coupled with an explicitly defined question about the IA symptom 
onset in the study questionnaire, helped to minimize the risk of recall bias for patient-
reported symptom onset. Third, our patient population had similar baseline and disease 
characteristics compared to cohorts of patients with IA from other countries, adding to the 
external validity, or generalizability, of the study results. Fourth, we minimized the risk of 
exposure misclassification and reporting bias by using only laboratory confirmed influenza 
A and B cases retrieved from the Canadian influenza surveillance program. Fifth, to 
quantify the effect of influenza on IA onset, we applied the time series regression analysis 
at the population level, where traditional epidemiological confounders such as age, sex, 
health status that do not significantly change from month to month, is not a concern. Lastly, 
we ensured methodological rigor of the study results by specifying a priori all the statistical 
analyses. 
4.5 Study Limitations 
 Although there are many strengths of our research, it has several limitations. First, 
we restricted our systematic review and meta-analysis to studies published in English. It is 
possible that non-English studies could have potential impact on the estimated results from 
our analysis. Second, observational study designs are the only ethical and practical designs 
to assess the odds/risk of RA after viral exposures. Therefore, the majority of the studies 
had potential for biases, such as selection, observation and attrition bias. We noted a 
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considerably low quality of evidence that led to heterogeneity attributable to variability 
between studies with regards to study protocols and quality, patient characteristics, poor 
matching and differences in laboratory analyses. Many authors failed to describe case and 
control ascertainment, prognostic imbalances, handling of missing data, and power and 
sample size calculations.  
There are several limitations of the time series analysis that we conducted. First, 
participation in the CATCH is voluntary, therefore not all patients with IA were included 
and there may be more IA onsets in the reference population. Second, there is a risk of 
ascertainment bias and underreporting of influenza cases. Influenza-related 
hospitalizations can be missed, either because testing is not performed, because cases may 
be attributed to other health-related conditions, or because patients do not report their 
illness to health care providers. Third, there might be unknown confounding factors that 
have month to month variability, but could not be addressed in this study.  
4.6 Recommendations for Future Research 
The studies of this thesis represent an important step in better understanding RA 
etiology. Research on the effect of viruses on the risk of RA have had controversial results. 
Our systematic review and meta-analysis analyzed and summarized the available body of 
evidence related to the risk of RA after different viruses. Future research should focus on 
exploring the effects of other putative viral infections on the risk of RA using the 
methodologically strongest possible observational studies. Our study was also the first to 
conduct a time series analysis of a large inception cohort of early IA and its association 
with influenza outbreaks at the population level. In terms of future research directions, it 
would be interesting to look at the effect of influenza exposure on the risk of IA at the 
individual level. This might be particularly informative if the studies could test mechanistic 
biological explanations by examining different aspects of immune function such as 
molecular mimicry. Also, since the course of IA/RA can differ between children and adults, 
future research should focus on the time series analysis of IA/RA in children and the 
association between influenza and the risk of IA/RA.    
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4.7 Conclusions 
RA is a one of the most common rheumatic diseases with an estimated prevalence 
in Canada of 779-789 cases per 100,000, and 50-54 years average onset14. If left untreated, 
it can lead to chronic irreversible joint destruction and long-term disability15. A greater 
understanding of RA risk factors can positively impact both RA diagnosis and treatment at 
early stages.  
 This research significantly contributed to elucidating those viruses that can 
potentially trigger RA development. Our study demonstrated that RA onset has a tendency 
to cluster in winter, therefore adding a clue to the study of environmental factors in RA 
etiology.  
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Appendices 
Appendix A: Literature Review Search Strategy Terminology and Syntax. 
Table A-1. Database-specific search strategies. 
Concept  MEDLINE EMBASE CINAHL PUBMED, 
Cochrane library 
Keywords 
Rheumatoi
d arthritis 
exp Arthritis, 
Rheumatoid/ 
exp Arthritis, 
Rheumatoid/ 
 
(MH “Arthritis, 
Rheumatoid”) OR 
(MH “Arthritis, 
Infectious”)  
Rheumatoid 
arthritis AND 
viruses  
rheumatoid arthriti* 
OR chronic arthritis 
OR inflammatory 
arthritis OR early 
arthritis 
Viral 
infections 
Viruses/ 
Viruses/ 
 
(MH "Viruses") OR 
(MH "Influenza A 
Virus") OR (MH 
"RNA Viruses") 
OR (MH 
"Herpesviruses") 
OR (MH 
"Influenzavirus C") 
OR (MH "Influenza 
A Virus, H1N1 
Subtype") OR (MH 
"Influenza A Virus, 
H5N1 Subtype")  
 virus disease* OR 
viral infection* OR 
respiratory virus OR 
human parvovirus 
OR epstein-barr virus 
OR zika virus OR 
chikungunya virus 
OR hepatitis OR 
influenza OR flu   
Risk 
factors 
risk factor/ 
 
risk factor/ 
 
 
(MH "Risk 
Factors+")  
  
risk factor* OR 
predictor*  
Total 
citations 
4174 (881 
duplicates 
removed) 
750 (244 
duplicates 
removed) 
30 (21 duplicates 
removed) 
1770 (800 
duplicates 
removed) 
6724 (4778 after 
deduplication) 
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Figure A-1. Flow chart of study selection. 
  
Records identified through database 
searching 
(n = 4954) 
Additional records identified 
through other sources 
(n = 1770) 
Records after duplicates removed 
(n = 4778) 
Records screened 
(n = 4778) 
Records excluded 
(n = 4460) 
Full-text articles assessed 
for eligibility 
(n = 318) 
Full-text articles excluded, with 
reasons (n = 255) 
Review article (114) 
No/Inappropriate control (37) 
Not RA/No outcome data (26) 
Abstract only (17) 
Not in English (15) 
Duplicates (12) 
Wrong setting (13) 
Not virus (11) 
Wrong patient population (10) 
 
 
Backward citation (n=15) 
Studies included in 
qualitative synthesis 
(n = 78) 
Studies included in quantitative synthesis 
(meta-analysis) (n=48) 
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Appendix B: Quality of Included Studies. 
Table B-1. Quality of included studies using modified Downs and Black checklist.
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Appendix C: Characteristics of Included Studies. 
Table C-1. Characteristics of included case-control studies.  
      Cases Controls Viral 
exposur
e 
(Antibo
dies 
against 
viral  
antigen
s) 
Matching Findings Cut-
off 
levels 
for 
serop
o-
sitivit
y 
Study Virus  Study 
locatio
n 
Tot
al 
Source 
of 
cases/di
agnosti
c 
criteria 
Fema
le to 
male 
ratio 
Age, 
mean 
(range or 
+- SD), 
years  
RA 
therapy 
Tot
al 
Source of 
controls 
Fema
le to 
male 
ratio 
Age, 
mean 
(range or 
+- SD), 
years 
Caliskan R 
et al. (34) 
PVB19 Turkey 31 RA 
ACR 
(year is 
not 
stated) 
26F/5
M 
45.7 Not 
stated 
50 Healthy 
blood 
donors 
40F/1
0M 
40.9 IgG, 
IgM ; 
DNA 
isolatio
n 
No A statistically 
significant 
difference was 
found between 
RA and 
controls for 
PVB19 IgM 
positivity 
No  
Cassinotti P 
et al. (27) 
PVB19 Switzer
land 
13 RA 
(criteria 
are not 
stated) 
Not 
stated 
Not 
stated 
Not 
stated 
11 Mechani
cal 
arthropat
hies 
Not 
stated 
Not 
stated 
IgG, 
IgM  
No The 
prevalence of 
IgG and IgM 
anti-PVB19 
antibodies was 
comparable 
between cases 
and controls 
No 
101 
.  
Chen Y-S et 
al. (29) 
PVB19 Taiwan 78 RA 
ACR 
1987 
63F/1
5M 
Not 
stated 
Not 
stated 
55 51-
trauma, 
4-OA 
37F/1
8M 
Not 
stated 
IgG, 
IgM; 
DNA 
isolatio
n 
Age, sex The 
prevalence of 
PVB19 
infection (IgG 
or IgM 
antibodies, 
DNA ) were 
significantly 
higher in RA 
patients than 
controls 
No  
Cohen B et 
al . (38) 
PVB19 UK 39 RA 
ARA 
1958 
24F/1
5M 
54.8 (16-
79) 
Not 
stated 
69 Healthy 
subjects 
48F/2
1M 
45.2 (19-
75) 
IgG, 
IgM; 
DNA 
isolatio
n 
No The 
prevalence of 
anti-PVB19 
IgG was 
significantly 
higher in RA 
than controls. 
IgM 
antibodies 
were found in 
2 RA and in 
none of 
controls 
No  
Hajeer A et 
al. (28) 
PVB19 UK 155 RA 
ACR 
1987 
67F/9
M 
 53.4+-
12.2 
Not 
stated 
155 RA 
discorda
nt twin 
pairs 
Not 
stated 
53.4+-
12.2 
IgG   Age No association 
between 
exposure to 
PVB19 and 
susceptibility 
to RA was 
found 
0 or 
1-
negati
ve, 2 
or 3-
positi
ve 
102 
.  
Jobanputra P 
et al. (40) 
PVB19 Scotlan
d 
503 RF-
tested 
subject
s 
347F/
156M 
45.0 Not 
stated 
348 Blood 
donors 
144F/
204 
33-37 DNA 
isolatio
n 
No Similar N of 
cases and 
controls were 
RF(+). 23 vs 2 
samples were 
PVB19 
positive.  
No 
Kerr J et al. 
(37) 
PVB19 Ireland 26 RA 
ACR 
1987 
21F/5
M 
64 (44-
82) 
Not 
stated 
26 OA 
patients 
18F/8
M 
68.2 (51-
88) 
IgG, 
IgM  
No Comparable 
number of 
patients in 
both groups 
had evidence 
of previous 
PVB19 
infection 
(IgG). All 
patients in 
both groups 
were IgM-
negative. 
PVB19 was 
present in 
synovium of 
similar 
number of 
patients and 
controls  
No 
103 
.  
Kozireva S 
et al. (35) 
PVB19 Latvia 100 RA 
ACR 
1987 
72F/2
8M 
55 (21-
81) 
68-
DMAR
D 
and/or 
prednis
one 
94 Healthy 
blood 
donors 
48F/4
6M 
35 (19-
58) 
IgG, 
IgM 
No Comparable 
number of 
cases and 
controls were 
seropositive 
for IgM and 
IgG anti-
PVB19 
antibodies. 
Significant 
difference 
between cases 
and controls 
for B19 DNA 
positivity. 
No 
Naciute M et 
al. (30) 
PVB19 Lithuan
ia 
Latvia 
118 RA 
ACR/E
ULAR 
2010 
99F/1
9M 
58.3+-13 DMAR
Ds 
49 Healthy 
subjects 
37F/1
4M 
50.2+-
11.3 
IgG, 
DNA 
isolatio
n 
Age, sex PVB19 DNA 
were 
comparable in 
cases and 
controls. 
B19V DNA in 
cell-free 
plasma was 
detected 
significantly 
more often in 
RA patients 
than in 
controls  
No  
104 
.  
Nikkari S et 
al. (33) 
PVB19 Finland 28 RA 
(ACR 
1987) 
Not 
stated 
Not 
stated 
Not 
stated 
18 Reactive 
arthritis 
Not 
stated 
Not 
stated 
IgG, 
IgM, 
DNA 
No PBV19 IgG 
and IgM 
antibodies 
were only 
investigated in 
early RA 
group and 
were detected 
in the majority  
of them. B19 
specific DNA 
was detected 
in 2 early RA 
patients   
No 
Pugliese A 
et al. (26) 
PVB19 Italy 6 RA 
(criteria 
are not 
stated) 
Not 
stated 
Not 
stated 
Not 
stated 
42 Healthy 
blood 
donors 
Not 
stated 
Not 
stated 
IgG No Comparable 
number of 
cases and 
controls were 
seropositive 
for PVB19  
No 
Saal J et al. 
(36) 
PVB19 Germa
ny 
20 RA 
ACR 
1987 
14F/6
M 
51+-4 8-
prednis
one, 
14-
DMAR
Ds 
34 Healthy 
blood 
donors 
Not 
stated 
Not 
stated 
IgG, 
DNA 
isolatio
n   
No Comparable 
number of 
cases and 
controls were 
IgG positive. 
Prevalence of 
PVB19 DNA 
was similar in 
RA and 
controls 
No  
105 
.  
Takahashi Y 
et al. (39) 
PVB19 Japan 25 RA 
ACR 
1987 
Not 
stated 
Not 
stated 
Not 
stated 
54 Healthy 
subjects 
Not 
stated 
Not 
stated 
DNA 
isolatio
n 
No All controls 
and 5 cases 
were PVB19 
DNA positive.  
No  
Taylor H et 
al. (25) 
PVB19 UK 21 RA 
(criteria 
are not 
stated) 
1F/8
M 
54 (29-
75) 
Not 
stated 
25 Early 
synovitis 
12F/1
3M 
51 (21-
78) 
IgG, 
IgM  
No IgM and IgG 
anti-PVB19 
antibodies 
were detected 
in comparable 
number of 
cases and 
controls 
No 
Sherina N et 
al. (32) 
PVB19
, EBV, 
CMV 
Sweden 990 RA 
ACR 
1987 
700F/
290M 
50.5+-
12.7 
No 
DMAR
D 
700 Populatio
n, aged 
18–70 
years, 
living in 
parts of 
Sweden 
during 
May 
1996–
Decembe
r 2005 
500F/
200M 
51.5+-
11.9 
IgG to 
VCA, 
CMV, 
PVB19 
Age, sex, 
residenti
al area  
Overall, the 
prevalence of 
anti-PVB19, -
EBV and -
CMV 
antibodies was 
high and 
comparable 
between cases 
and controls. 
Subgroup 
analysis 
showed 
marginally 
higher 
frequency of 
anti-PVB19 
positivity in 
RA patients 
compared to 
 ≥ 6.0 
arbitr
ary 
units 
(AU)/
ml for 
anti-
CMV 
IgG, 
and > 
1.0 
index 
value 
for 
both 
anti-
EBV 
IgG 
and 
anti- 
106 
.  
controls 
(p=0.046) 
B19 
IgG 
Alspaugh M 
et al. (53) 
EBV USA 61 RA 
ARA 
1973 
Not 
stated 
Not 
stated 
Not 
stated 
16 Healthy 
subjects  
Not 
stated 
Not 
stated 
EBNA, 
VCA 
IgG 
No Compared to 
healthy 
controls, 
higher 
frequencies of 
elevated VCA 
and EA titers 
were detected 
in patients' 
sera. No such 
association 
was found 
with regard to 
anti-EBNA 
antigens.  
>=32
0 for 
EBN
A, 
VCA, 
>=10 
for 
EA 
107 
.  
Alvarez-
Lafuente R 
et al. (62) 
CMV, 
EBV, 
HHV-6 
Spain 61 RA 
ACR 
1987 
41F/2
0M 
67.5 (23-
91) 
20-
MTX, 
14-
MTX+
gold 
salts, 2-
MTX+
LF, 5-
MTX+
TNF-a 
blocker
s 
77 Healthy 
subjects 
29F/4
8M 
32.6 (18-
57) 
DNA 
and 
viral 
load of 
CMV, 
EVB, 
HHV-6 
No In PBMC, 
only EBV was 
significantly 
more often in 
RA cases than 
in controls. 
HHV-6 was 
found 
significantly 
more often in 
RA cases than 
in controls. No 
difference in 
virus detection 
was observed 
depending on 
current 
therapy  
No 
Balandraud 
N et al. (60) 
EBV France 84 RA 
ACR 
1987 
Not 
stated 
Not 
stated 
43-
biologi
cs, 42-
DMAR
D, 14-
no 
therapy 
69 Healthy 
subjects 
Not 
stated 
Not 
stated 
DNA 
load in 
PBMC 
No EBV was 
detected in 
comparable 
number of 
cases and 
controls. Viral 
load was 
significantly 
higher in RA 
cases than in 
controls. No 
difference in 
virus detection 
was observed 
depending on 
No  
108 
.  
current 
therapy, age at 
onset and 
disease 
duration 
Blaschke S 
et al. (45) 
EBV Germa
ny 
55 RA 
ACR 
1987 
43F/1
2M 
54 (18-
77) 
42/55 
Prednis
one or 
DMAR
D 
60 Healthy 
subjects 
48F/1
2M 
Mean 50 
(18-65) 
IgG/M 
to 
EBNA-
1, 
VCA, 
EA, 
DNA 
isolatio
n 
Age, sex Two-fold 
increase of 
IgG anti-
EBNA-1 
antibodies(p=0
.029) in RA 
patients. No 
significant 
difference 
between RA 
and controls in 
VCA and EA 
antibodies. 
Not 
stated 
Catalano M 
et al. (43) 
HSV, 
VZV, 
CMV 
USA 47 RA 
(criteria 
are not 
stated) 
Not 
stated 
Not 
stated 
Not 
stated 
48 Helathy 
subjects 
Not 
stated 
Not 
stated 
anti-
HSV, 
VZV, 
CMV 
antibod
ies (Ig 
type is 
not 
stated) 
No Controls had 
significantly 
lower anti-
EBNA titers 
than cases. 
Anti-VCA, 
anti-HSV, 
anti-CMV and 
anti-VZV 
titers were 
comparable 
between cases 
and controls.  
Not 
stated 
109 
.  
Davies J et 
al. (63) 
EBV Austral
ia 
50 RA 
ACR 
1987 
36F/1
4M 
63.3 (32-
97) 
Not 
stated 
43 Healthy 
subjects 
Not 
stated 
Not 
stated 
EBNA-
1 IgG 
No Reactivity 
with EBNA -1 
was similar in 
cases and 
controls 
No 
Draborg A 
et al. (54) 
EBV Denma
rk 
20 RA 
ACR 
1987 
14F/6
M 
52.4 (27-
72) 
Not 
stated 
20 Healthy 
subjects 
12F/8
M 
32.1 (25-
63) 
EA 
IgA/G/
M 
No A significant 
higher 
prevalence of 
anti-EA IgA 
and IgM 
antibodies was 
observed in 
sera from RA 
patients 
compared to 
controls.  
0.2, 
0.035 
and 
0.1, 
regar
ding 
IgG-, 
IgA- 
and 
IgM- 
EBV-
EA 
antibo
dies 
Ferraro A et 
al. (64) 
EBV, 
CMV, 
VZV 
Canada 29 RA 
ACR 
1987 
15F/1
4M 
60+-12.7 Prednis
one, 
DMAR
D (N 
are not 
stated) 
17 Healthy 
subjects 
14F/3
M 
35.3+-
1.8  (23-
50) 
CMV 
IgG/M; 
IgG/M 
EBNA; 
IgG 
VZV 
No Similar 
frequencies of 
anti-viral 
antibodies was 
observed in 
RA and 
controls 
Not 
stated 
Ferrell P et 
al. (55) 
EBV USA 89 RA 
ARA 
1959 
42F/4
7M 
56.0 28/85 
Prednis
one, 
4/85 
cycloph
53 37 
healthy 
subjects, 
16-OA 
patients 
28F/2
5M 
51.0 EBNA, 
VCA, 
EA IgG 
No Anti-EA 
antibodies 
were 
significantly 
higher 
anti-
VCA
>1;16
0,anti
-
110 
.  
ospham
ide 
detected in 
patients with  
RA than in 
controls 
(p<0.001) 
EA>1
;20 
Goldstein B 
et al. (51) 
EBV, 
CMV  
USA 87 RA 
ACR 
1987 
Fema
le 
nurse
s 
54.9+-
8.3 
Not 
stated 
87 Healthy 
subjects 
Fema
le 
nurse
s 
54.8+-
8.2 
VCA, 
EA, 
EBNA-
1, 2,  
CMV 
IgG 
Matching 
for date 
of blood 
donation, 
birth 
year, 
menopau
sal 
status, 
postmen
opausal 
hormone 
use 
No 
relationship 
between EBV 
serologic 
responses and 
the risk of RA 
was found. 
Marginally 
higher number 
of CMV-
positive cases 
in cases 
compared to 
controls. 
anti-
EBN
A>1;
80, 
anti-
VCA
>1;51
20, 
anti-
EA.1;
20 
Henle G et 
al. (56) 
EBV USA 28 RA 
ARA 
1973 
Not 
stated 
Not 
stated 
Not 
stated 
51 24-non-
EBV 
infected  
healthy 
subjects; 
27-
miscellan
eous 
donors 
with 
serologic
al 
evidence 
of past 
Not 
stated 
  VCA, 
EA 
IgM/G/
A 
No All RA 
patients had 
anti-VCA IgG 
antibodies, and 
71% had IgM 
antibodies. 
IgM titers 
significantly 
correlated with  
RF titers. 
None of the 
controls had 
detectable 
anti-VCA IgM 
RF 
titers 
>=40, 
anti-
VCA 
IgM>
=40 
were 
consi
dered 
as 
positi
ve 
111 
.  
primary 
EBV 
infection
s 
or IgG 
antibodies 
Jorgensen K 
et al. (31) 
EBV, 
PVB19 
Norwa
y 
49 PreRA  31F/1
8M 
Median 
41 (21-
64) 
Not 
stated 
245 Healthy 
blood 
donors 
155F/
90M 
Not 
stated 
EBNA, 
VCA 
IgG; 
PVB19 
IgG 
Matching 
for sex, 
birth 
date, N 
of blood 
donation
s, date 
for recent 
blood 
donation 
IgG antibodies 
against 
Epstein-Barr 
virus and 
parvovirus 
B19 did not 
differ 
significantly 
between case 
and control 
sera. 
0.250 
OD 
for 
EBV; 
0190 
OD 
for 
PVB1
9 
33 RA 
ACR 
1987 
20F/1
3M 
Median 
50 (24-
83) 
112 
.  
Lunemann J 
et al.(44) 
EBV,  
CMV 
Germa
ny 
25 RA 
ACR 
1987 
19F/6
M 
58.7+-
9.1 
25-
Prednis
one, 
10-
MTX, 
6-TNF-
a 
blocker
s, 1-
AZA, 
1-MPM 
20 Healthy 
subjects 
8F/12
M 
58.2+-
6.3 
EBNA-
1, 
VCA, 
EA, 
HCMV 
IgG 
Age Comparable 
number of 
cases and 
controls were 
positive for 
CMV, EBNA -
1 and VCA 
antibodies. EA 
antibodies 
were 
significantly 
more often 
detected in 
cases 
compared to 
controls. No 
difference in 
seropositivity 
was detected 
depending on 
the 
presence/abse
nce of therapy 
No  
Meron M et 
al. (41) 
EBV,  
CMV 
Colom
bia 
187 RA 
(criteria 
are not 
stated) 
Not 
stated 
Not 
stated 
Not 
stated 
140 Healthy 
subjects 
Not 
stated 
Not 
stated 
EA, 
EBNA, 
VCA, 
CMV 
IgG 
No RA patients 
had higher 
rates of EA 
anti-EBV 
antibodies 
compared to 
healthy 
controls 
(21.7% vs. 
7.1%, 
No  
113 
.  
p<0.001). 
Compared to 
the controls, 
fewer RA 
patients had 
previous CMV 
infection (89% 
vs.93%, 
p=0.08) 
Male D et al. 
(72) 
CMV UK 37 RA 
ARA 
1959 
Not 
stated 
Not 
stated 
Not 
stated 
22 Healthy 
subjects 
Not 
stated 
Not 
stated 
CMV-
EA (Ig 
type is 
not 
stated) 
No Anti-CMV 
antibodies 
were observed 
in comparable 
number of 
cases and 
controls. 
Higher titers of 
antibodies 
were detected 
in cases 
compared to 
controls.  
1/15-
weakl
y 
positi
ve 
sera, 
1/60-
strong
ly 
positi
ve 
sera 
Mehraein Y 
et al. (61) 
EBV, 
CMV, 
PVB19 
 
Germa
ny 
29 RA 
ACR 
1987 
20F/9
M 
Not 
stated 
Not 
stated 
34 26-UA, 
6-PsA, 2-
healthy 
controls 
14F/1
2M 
6M 
1F/1
M 
Not 
stated 
EA, 
CMV 
DNA 
No EBV and 
CMV 
infections was 
equally 
detected in 
cases and 
controls.  
PVB19 DNA  
was more 
No  
114 
.  
often detected 
in cases than 
controls  
McDermott 
M et al. (42) 
EBV Ireland 53 RA 
(criteria 
are not 
stated) 
Not 
stated 
Not 
stated 
Penicill
amin or 
gold 
salts 
37 Healthy 
subjects 
Not 
stated 
Not 
stated 
EA, 
VCA, 
EBNA 
IgG/M 
No A higher 
proportion of 
RA cases than 
controls were 
EBV-positive  
No  
Mousavi-
Jazi M et al 
(65) 
CMV, 
EBV, 
HSV-1, 
HSV-2, 
VZV, 
HHV-6 
Sweden 34 RA 
(criteria 
are not 
stated) 
30F/4
M 
58 (31-
82) 
All 
patients 
receive
d RA 
therapy  
12 OA 
patients 
7F/7
M 
Mean 72 
(45-87) 
IgG to 
CMV, 
HSV, 
VZV, 
HHV; 
VCA, 
EBNA-
1, EA ; 
DNA 
isolatio
n 
No The 
prevalence of 
antibodies to 
all herpes 
viruses were 
comparable 
between cases 
and controls. 
Higher titters 
of anti-VCA 
antibodies 
were detected 
in RA group.    
No  
115 
.  
Musiani M 
et al. (46) 
EBV, 
CMV  
Italy 35 RA 
ARA 
1958 
Not 
stated 
28-65 20-
prednis
one, 
11-
gold, 2-
antimal
arial 
40 Healthy 
subjects 
Not 
stated 
Not 
stated 
VCA, 
EBNA-
1, EA, 
CMV 
(Ig type 
is not 
stated) 
Age, sex All cases and 
controls had 
detectable 
antibodies to 
VCA and 
EBNA, 
indicating that 
all had 
previously 
been infected 
with EBV. 
Statistically 
significant 
increase in the 
titers of anti-
VCA, EA and 
EBNA and 
anti-CMV 
antibodies was 
observed in 
cases 
compared to 
controls 
Anti-
VCA
>=1/3
20, 
anti-
EA>=
1/20, 
anti-
EBN
A>=1
/10 
(for 
recent
ly 
reacti
vated 
infect
ion); 
>=1/2
0 for 
CMV 
Nakabayashi 
K et al. (47) 
EBV Japan 40 RA 
ARA 
(year is 
not 
stated) 
Not 
stated 
44.0 Not 
stated 
30 Healthy 
subjects 
40 Not 
stated 
VCA, 
EBNA 
IgG 
Age, sex No statistically 
significant 
differences in 
anti-EBNA 
and anti-VCA 
IgG antibody 
titers  were 
observed 
between cases 
and controls  
No  
116 
.  
Ng K et al. 
(66) 
EBV UK 124 RA 
ARA 
1958 
Not 
stated 
Not 
stated 
16-
prednis
one, 
25-
DMAR
Ds 
50 Healthy 
subjects 
Not 
stated 
Not 
stated 
VCA, 
EBNA 
(type of 
Ig is 
not 
stated) 
No Higher 
frequency of 
anti-VCA and 
-EBNA 
antibodies was 
detected in 
cases than in 
controls 
No  
Phillips P et 
al. (48) 
EBV,  
CMV 
USA 33 RA 
ARA 
1958 
27F/6
M 
55.7 (22-
74) 
Not 
stated 
Not 
stat
ed 
Healthy 
blood 
donors 
Not 
stated 
Not 
stated 
Not 
stated 
Age, sex The 
prevalence of 
anti-EBV and 
anti-CMV 
antibodies was 
similar in 
cases and 
controls  
No  
Saal J et al. 
(69) 
EBV Germa
ny 
84 RA 
ACR 
1987 
59F/2
5M 
57 (23-
71) 
24-
prednis
one, 
32-
DMAR
DS 
67 OA 42F/2
5M 
51 (24-
80), 64 
(48-74) 
VCA 
IgG 
No EBV 
DNA/RNA 
were 
significantly 
more often 
detected in 
sera and 
synovium of 
cases than  
controls 
No  
Sculley T et 
al. (67) 
EBV  Austral
ia 
72 RA 
ARA 
1958 
Not 
stated 
Not 
stated 
Not 
stated 
46 Helathy 
subjects 
Not 
stated 
Not 
stated 
EBNA-
1,2 (Ig 
type is 
not 
stated) 
No Significantly 
more cases 
than controls 
were anti-
No  
117 
.  
EBNA-2 
positive 
Shirodaria P 
et al. (49) 
EBV, 
rubella, 
measles 
Ireland 26 RA 
ARA 
1958 
17F/9
M 
51.8 (26-
75) 
Not 
stated 
26 Healthy 
blood 
donors 
17F/9
M 
52 (27-
74) 
VCA, 
EBNA-
1 IgG; 
HA a, 
HL IgG  
Age, sex Anti-measles, 
anti-rubella 
IgG 
antibodies, as 
well as 
antibodies to 
VCA and 
EBNA were 
found in serum 
of both cases 
and controls. 
Mean titers of 
all antibodies 
were 
significantly 
higher in cases 
compared to 
controls  
No  
Silverman S 
et al. (50) 
EBV  USA 24 RA 
ARA 
1958 
Not 
stated 
46 (30-
58) 
Not 
stated 
20 Healthy 
subjects 
Not 
stated 
40 (26-
56) 
EA, 
EBNA, 
VCA 
IgG 
Age, sex VCA and 
EBNA 
frequencies 
are not 
presented. RA 
patients had 
significantly 
higher mean  
titers of 
antibodies to 
>=1/1
0 for 
EA 
118 
.  
EBNA, but not 
to VCA. An 
increased 
frequency of 
anti-EA was 
observed in  
cases 
Venables P 
et al. (58) 
EBV UK 100 RA 
ARA 
1958 
Not 
stated 
Not 
stated 
Not 
stated 
33 Healthy 
subjects 
Not 
stated 
21-62 VCA 
(Ig type 
is not 
stated) 
No The 
prevalence of 
anti-VCA 
antibodies was 
comparable in 
cases and 
controls.  
>=1/1
0 for 
EA 
Venables P 
et al. (57) 
EBV, 
CMV 
UK 41 RA 
ARA 
1958 
38F/9
M 
60.9 Not 
stated 
26 Healthy 
subjects 
23F/3
M 
42.3 VCA, 
CMV 
IgG 
No IgG anti-CMV 
and anti-VCA 
prevalence and 
titers were 
comparable 
between RA 
and controls.   
<1;16 
Westergaard 
M et al. (59) 
EBV  Denma
rk 
77 RA 
ACR/E
ULAR 
2010 
59F/1
8M 
55.5 (27-
78) 
50-
MTX, 
23-
prednis
one, 
28-
TNF-a 
28 Healthy 
subjects 
27F/1
M 
36.6 (22-
61) 
EA, 
EBNA-
1 
IgG/M/
A 
No Significant 
difference in 
EA IgG and 
IgA levels 
between RA 
and controls. 
EBNA-1 
IgG/M/A 
14.53
vfor 
EAD 
IgG, 
1.50 
U/mL 
for 
EBN
119 
.  
blocker
s 
antibodies 
were 
significantly 
more often 
detected in RA 
cases than in 
controls 
A-1 
IgG  
Yao Q et al. 
(70) 
EBV  UK 33 RA 
ARA 
1958 
Not 
stated 
36-74 RA 
therapy 
was 
withdra
wn 6 
weeks 
prior to 
the 
study 
26 Healthy 
subjects 
Not 
stated 
22-64 VCA, 
EA 
No Comparable 
number of RA 
patients and 
controls were 
negative for 
anti-EBV 
antibodies. 
The titer of 
anti-VCA and 
anti-EA 
antibodies 
were markedly  
higher in RA 
than in 
controls 
No  
Yazbek M et 
al. (52) 
EBV  Brazil 140 RA 
ACR 
1987 
122F/
18M 
54.2+-
11.3 (25-
82) 
Not 
stated 
143 Healthy 
subjects 
123F/
20M 
55.8+-
13.4 
EBNA-
1 (Ig 
type is 
not 
stated) 
Age, sex, 
ethnicity  
No significant 
differences 
were observed 
between cases 
and the 
controls in 
terms of the 
positivity and 
the mean  
No 
120 
.  
levels of anti-
EBNA-1 
antibodies 
Youinou P 
et al. (68) 
EBV France 100 RA 
ACR 
1987 
89F/1
1M 
48 (25-
69) 
Not 
stated 
50 Healthy 
subjects 
Not 
stated 
47 (23-
74) 
EBNA-
1, 
VCA, 
EA,  
EBNA-
2a, 
EBNA-
2b IgG 
No Increased 
frequency of 
antibodies to 
EBNA-2b was 
observed in 
cases. 
Comparable  
frequency of 
other 
antibodies was 
detected in 
cases and 
controls.  
>1;10 
for 
VCA 
and 
EBN
A-1; 
>1;20 
for 
EA; 
>1;5 
for 
EBN
A-2 
Zhang L et 
al. (71) 
EBV, 
HSV 
Finland 62 RA 
ACR 
1987 
39F/2
3M 
53.2+-
15.6 
Not 
stated 
49 Healthy 
blood 
donors 
16F/3
3M 
40.9+-
9.8 
VCA 
IgG/M, 
HSV 
IgG; 
DNA 
extracti
on 
No IgG anti-VCA 
were positive 
in all cases and 
controls. IgM 
were not 
detected 
almost in all 
cases and 
control. HSV 
IgG were 
comparably 
detected in 
No  
121 
.  
cases and 
controls 
Vandenbrou
cke J et al. 
(100) 
Non-
specific 
bronch
o-
pulmon
ary 
infectio
n 
Netherl
ands 
329 RA 
ARA 
1958 
Fema
les  
Not 
stated 
Not 
stated 
384 OA 
and/or 
soft 
tissue 
diseases 
Fema
les 
Not 
stated 
NA Date of 
birth, 
sex-
matching
; 
stratificat
ion for 
age, age 
at onset, 
duration 
of 
disease 
The  frequency 
of first 
occurrence of 
infection 
(“never” 
versus “before 
onset of joint 
disease” 
versus “after 
onset”) did not 
differ between 
RA patients 
and controls 
NA 
Sandberg M 
et al. (111) 
Sinusiti
s 
tonsillit
is 
pneum
onia 
Sweden 283
1 
RA 
ACR 
1987 
2024
F/807
M 
4 age 
groups 
Not 
stated 
357
0 
RA-free 
controls 
2564
F/100
6M 
4 age 
groups 
NA Matching 
for age at 
diagnosis
, calendar 
year, sex 
area of 
residence 
The odds of 
infection were 
comparable 
between cases 
and controls 
NA 
122 
.  
Bosma t et 
al. (97) 
Rubella 
virus 
UK 12 RA 
(criteria 
are not 
stated) 
6F/6
M 
60.9 (30-
86) 
Not 
stated 
22 OA 
patients 
4F/18
M 
59.1 (29-
80) 
IgG ; 
RNA 
isolatio
n 
Age IgG anti-
rubella 
antibodies 
were present 
in all cases 
and controls. 
IgM 
antibodies 
were not 
detected in 
both groups. 
There was no 
evidence of 
rubella virus 
in synovial 
samples 
No  
Ejtehadi H 
et al. (98) 
HERV 
K-10 
UK 40 RA 
ACR 
(year is 
not 
stated) 
Not 
stated 
61 (34-
85) 
DMAR
Ds 
27 Healthy 
subjects 
Not 
stated 
47 (21-
80) 
RNA No Enhanced m-
RNA 
expression 
was found in 
RA patients 
compared to 
controls 
No  
Adebajo A 
et al. (75) 
HBV UK 58 RA 
ARA 
1959 
34F/2
4M 
38.2 (14-
83) 
Not 
stated 
166 Blood 
donors 
and 
healthy 
controls 
84F/8
2M 
40 (17-
80) 
HBs-
Ag 
No 15.5% vs 
5.4% of RA 
and controls 
were HBs-Ag 
positive, 
respectively 
(p<0.05) 
No  
123 
.  
Barbosa V et 
al. (81) 
HCV Brazil 89 RA 
(criteria 
are not 
stated) 
Not 
stated 
38.3 (16-
77) 
Not 
stated 
103 Other 
types of 
arthritis 
  38.3 (16-
77) 
anti-
HCV 
antibod
ies 
No 3.4% cases 
compared to 
zero controls 
were anti-
HCV positive  
No  
D'Amico E 
et al. (82) 
HCV Italy 49 RA 
ARA 
(year is 
not 
stated) 
42F/7
M 
61 (18-
81) 
Not 
stated 
83 OA 
patients 
71F/1
2M 
59 (20-
97) 
anti-
HCV 
antibod
ies 
No 7 cases vs 1 
control were 
anti-HCV 
positive 
(p<0.005). 
None of them 
was 
cryoglobulin 
positive. 
No  
Hoofnagle J 
et al. (76) 
HBV USA 74 RA 
ARA 
(year is 
not 
stated) 
Not 
stated 
Not 
stated 
Not 
stated 
30 Blood 
donors 
Not 
stated 
Not 
stated 
anti-
HB-Ag 
No Only one 
patient from 
RA group and 
none from 
controls were 
HBs-Ag 
positive 
No  
Hsu F et al. 
(83) 
HCV  USA 196 Probabl
e RA 
ACR 
1987 
113F/
83M 
72 (IQR 
65-80) 
Not 
stated 
445
6 
Non-RA 
subjects 
2,250
F/2,2
06M 
71 (IQR 
65-78) 
HCV, 
HCV-
RNA, 
RF 
Age>60 The frequency 
of HCV 
antibodies was 
comparable 
between cases 
and controls  
No  
124 
.  
Hsu C-S et 
al. (77) 
HBV Taiwan 389
69 
RA 
ACR 
1987 
30,66
5F/8,
304M 
53.4+-14 4528-
biologi
c 
agents 
701
476 
Non-RA 
subjects 
343,4
92F/3
57,98
4M 
41.7+-
16.9 
Codes 
for 
HBV 
diagnos
is were 
used to 
identify 
patients 
Multivari
able 
regressio
n 
analysis 
Unadjusted 
odds of HBV 
were 
comparable 
between cases 
and controls. 
After 
adjustment for 
potential 
confounders, 
the odds of 
HBV were 
significantly 
higher in cases 
compared to 
controls (1.13, 
95% CIs: 
1.08–1.17). 
No  
Jeong H et 
al. (73) 
HBV Korea 578
522 
RA 
(criteria 
were 
not 
applied
) 
444,8
83F/1
33,63
9M 
57.5+-1 Not 
stated 
368
746
36 
Non-RA 
subjects 
18,58
4,817
F/18,
289,8
19M 
45.1+-
0.2 
NA Multivari
able 
regressio
n 
analysis 
The overall 
prevalence of 
RA was 1.5%. 
Patients were 
considered as 
having RA if 
they answered 
in the 
questionnaire 
that RA was 
diagnosed by 
their 
physician. The 
adjusted odds 
of HBV were 
No  
125 
.  
significantly 
higher in cases 
compared to 
controls (2.34 
(1.15–4.80) 
p=0.02). The 
adjusted odds 
of HCV were 
comparable 
cases and 
controls 1.47 
(0.18–11.80), 
p=0.7) 
Park Y et al. 
(80) 
HCV Korea 19 RA 
(criteria 
are not 
stated) 
Not 
stated 
Not 
stated 
Not 
stated 
40 Healthy 
subjects  
Not 
stated 
Not 
stated 
anti-
HCV 
antibod
ies 
No 31.6% cases 
and 0% of 
controls had 
antibodies to 
HCV (p-value 
is not 
presented) 
No  
Rivera J et 
al. (84) 
HCV  Spain 303 RA 
ACR 
1987 
236F/
67M 
58.3+-13 
(22-89) 
Not 
stated 
315 Healthy 
blood 
donors 
104F/
211M 
33.4+-
11.7 
anti-
HCV 
antibod
ies, 
cryoglo
bulins 
No Significantly 
higher 
prevalence of 
anti-HCV 
antibodies was 
observed in 
cases (7.6%) 
compared to 
controls 
(0.95%) 
(p<0.001) 
No  
126 
.  
Yilmaz  et 
al. (74) 
HCV, 
HBV 
Turkey 151
7 
RA 
ACR 
1987 
1,185
F/332
M 
49+-13.2 Not 
stated 
886 Ankylo-
sing 
spondy-
litis 
394F/
492M 
37.3+-
10.5 
HBs-
Ag, 
anti-
HCV 
No The 
prevalence of 
anti-HCV and 
HBs-Ag was 
comparable 
between cases 
and controls 
No  
RA – rheumatoid arthritis, OA- osteoarthritis, PsA – psoriatic arthritis, PVB19 – parvovirus B19, EBV – Epstein-Barr virus, EBNA – Epstein-Barr nuclear antigen, VCA – 
viral capsid antigen, EA – early antigen, CMV – cytomegalovirus, HBV – chronic hepatitis B, HBsAG – hepatitis B surface antigen, HCV – chronic hepatitis C, VZV – 
varicella zoster virus, HSV – herpes simplex virus, HHV – human herpes virus, HERV – human endogenous retrovirus . 
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Table C-2. Characteristics of included studies with other study designs. 
Study  Virus  Study 
location 
Study 
design 
Specimen 
(source of 
information) 
analyzed 
Sample 
size  
Population 
type 
Background 
medical therapy 
Female to 
male ratio 
Age, mean 
(range or +- 
SD), years  
Antibodi
es 
against 
antigens 
Follow-
up 
Findings 
Ferucci E 
et al. (85) 
HCV  USA cross-
sectional  
sera, 
questionnaires 
117 chronic 
HCV 
Absence of 
antiviral therapy 
(inclusion 
criterion) 
7F/110M 44.7 RF 
IgG/M/A
; ACPA 
RF 
IgG/M/
A; 
ACPA 
8/117 had HCV-
associated arthritis, 4 of 
whom were diagnosed RA 
(criteria are not stated). 
RF was commonly present 
in both with or without 
arthritis subjects.  
Su F-H et 
al. (79) 
HCV, 
HBV 
Taiwan retrospecti
ve cohort 
Codes for 
HBV, HCV or 
both were 
used to 
identify 
patients.  
10253 HCV DMARDs 5,084F/5,1
69M 
2 age 
groups: <50 
and >50 
years old 
(no mean 
age is 
stated) 
Not 
applied 
11 years 
maximu
m or 
until 
the 
diagnosi
s of RA 
All participants were RA-
free at baseline. After 
adjusting for covariates, 
chronic HCV infection 
was significantly 
associated with an 
increased risk of RA. The 
risk of RA among chronic 
HCV patients remained 
significant after restricting 
the analysis to those who 
were prescribed 
35652 HBV 14,936F/2
0,716M 
3987 HCV+HBV 1,747F/2,2
40M 
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DMARDS. There was a 
marginally significantly 
increased risk of RA in the 
group with combination of 
HCV and HBV infections 
Cacoub P 
et al. (86) 
HCV France cross-
sectional 
sera, 
questionnaires 
321 chronic 
HCV 
72/316-
interferon 
154F/167
M 
46+-16 (17-
92) 
anti-
HCV, 
HCV-
RNA; 
RF 
No RA (criteria are not stated) 
was diagnosed in 1 
patient. 107/280 were RF-
positive. 110/196 patients 
had mixed cryoglobulins. 
Significant association 
was found between the 
presence of mixed 
cryoglobulins and RF-
positivity 
Shim C et 
al. (78) 
HBV Korea cross-
sectional 
sera, 
questionnaires 
37660 
and 
1494  
Healthy 
subjects, 
HBs-Ag(+) 
subjects 
Not stated 14391F/23
269M and 
464F/1030
M 
40+-7 (15-
91) 
and40.4+-
6.6 (21-78) 
RF, 
HBs-Ag 
No 11.8% of HBs-Ag-positive 
subjects were RF positive 
compared with 3.4% of 
screening subjects without 
HBsAg (P<0.001). RF(+) 
was associated with the 
presence of HBs-Ag and 
HCV antibodies  in 
healthy subjects 
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Essackjee 
K et al. 
(95) 
CHIKV Mauritu
s 
cross-
sectional 
questionnaires 195 Suspicious 
for CHIKV 
subjects 
during 
CHIKV 
outbreak 
NSAIDs or 
paracetamol, 
19-prednisone 
143F/30M 52.1 NA Median 
27.5 
months 
173/195 were diagnosed 
with CHIKV. 136/173 
patients had persistent 
joint symptoms 27.5 
months after CHIKV. 
10/136 of patients fulfilled 
ACR 1987 criteria for RA 
Bouquillar
d E et al. 
(112) 
CHIKV Reunion 
Island 
case-
series 
sera 21 Recent 
CHIKV 
infection+p
ossible RA, 
no previous 
history of 
arthritis 
 Not stated 13F/8M 57.3+-12.2 RF, 
CHIKV 
IgG/M 
mean 
27.6+-
6.4 
months 
12 patients were RF(+), 6 
were ACPA(+). During 
the follow-up, 19 patients 
required DMARD, 6-
biological therapy 
Duran A et 
al. (94) 
CHIKV Bolivia, 
Argenti
na 
cross-
sectional 
medical 
records, sera 
202 Possible 
recent 
CHIKV 
Not stated 107F/15M 52.5+-13 RF, 
CHIKV 
IgG/M 
No 122 had confirmed 
CHIKV. 6 patients 
developed RF(+) RA de 
novo 
Kularatne 
S et al. (89) 
CHIKV Sri-
Lanka 
case-
series 
medical 
records, sera, 
survey 
512 Recent 
CHIKV 
 Not stated 275F/237
M 
35 (1-90)   36 
months 
230/512 patients 
developed chronic 
arthritic disability. 34/512 
had history of arthritis. 
102/230 recovered and 
128/230 developed 
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persistent arthritic 
disability (defined as pain, 
pain with swelling, 
limitation of movements, 
limitation of function, and 
bed ridden)  
Manimund
a S et al. 
(90) 
CHIKV India case-
series 
sera 203 CHIKV-
IgM 
positive 
patients 
Not stated 107F/96M 35 (IQR 25-
44) 
CHIKV-
IgM; RF, 
ACPA 
10 
months 
Among 94 patients with 
poly-, oligo- or 
monoarthritis, 34 satisfied 
developed RF(-)  RA 
(year of ACR criteria is 
not stated) 
Gauri  et 
al. (87) 
CHIKV India case-
series 
sera  200 Ophthalmol
ogy Medical 
Department 
outpatients 
Not stated Not stated Not stated CHIKV-
IgM  
2 years 5/200 patients were 
RF(+). RA criteria were 
not applied 
Javelle E et 
al. (88) 
CHIKV Reunion 
Island 
retrospecti
ve case-
series 
medical 
records 
159 Persistent 
joint 
symptoms 
following 
confirmed 
CHIKV 
Not stated 119F/40M 51 (16-80) ND 72 
months 
Among 159 patients, 40 
developed de novo RA 
after CHIKV. 12 were 
RF(+), 2 were ACPA(+).  
Rosario R 
et al. (92) 
CHIKV Domini
can 
case-
series 
sera 514 Recent 
CHIKV 
Not stated 447F/67M 53.7 Not 
stated 
No 344/415 developed 
arthritis. 370 required 
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Republi
c 
infection, no 
history of 
rheumatic 
diseases 
prednisone, 5 required 
therapy with disease-
modifying anti-rheumatic 
drugs.  
Miner J et 
al. (91) 
CHIKV USA case-
series 
medical 
records, sera 
10 Recent 
CHIKV 
infection, no 
history of 
rheumatic 
diseases 
Not stated 8F/2M 18-57 RF, 
ACPA 
(Ig types 
are not 
stated), 
CHIKV 
IgG 
2.5 
months 
Among 9 patients tested 
for RF and ACPA, none 
was positive for these 
antibodies. 8/10 patients 
met ACR 1987 criteria for 
seronegative RA 
Sepulveda-
Delgado J 
et al. (93) 
CHIKV Mexico case-
series 
sera, DAS-28 10 Recent 
CHIKV 
Not stated 6F/4M 48+-15 CHIKV-
RNA 
12 
months 
At baseline, polyarticular 
involvement was present 
in 7/10 cases, 6/10 
patients presented severe 
chronic arthritis (DAS-28 
>5.1), all patients were 
RF(+). After 3 months, 
only 2 patients remained 
chronic, but none of them 
fulfilled RA diagnostic 
criteria 
Yaseen H 
et al. (96) 
CHIKV Reunion 
Island 
Retrospec
-tive 
cohort 
sera, 
questionnaires 
403 Recent 
CHIKV 
Not stated 3F/400M Not stated self-
declared 
CHIKV 
30 124/403 participants (101 
CHIKV+/302 CHIKV-) 
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reported arthralgia and 57 
(14.1%) arthritis. 
Svec K et 
al. (99) 
Asian 
influen
za 
USA prospectiv
e cohort 
sera 106 Subjects 
before 
influenza 
epidemic 
No rheumatic 
disease 
53F/53M 29-50 Influenz
a-
antibody 
titers 
1-2 
months 
27/106 individuals 
showed a significant 
increase of antibodies to 
influenza A. RF was 
detected significantly 
more frequently in these 
27 subjects than in 79 
subjects with no increase 
in viral antibodies. RF was 
not detected in significant 
titer in pre-epidemic sera 
of these patients 
 
 
 
  
133 
.  
Appendix D: Publication Bias Assessment. 
                                                
                                                  D-1                                                                                                                   D-2 
                                                   
                                                  D-3                                                                                                                        D-4 
Figure D: D-1 - Funnel plot examining potential publication bias for PBV19 IgG in RA patients and controls (OR); D-2 - Funnel plot 
examining potential publication bias for EBNA IgG in RA patients and controls (OR); D-3 - Funnel plot examining potential publicat ion 
bias for VCA IgG in RA patients and controls (OR); D-4 - Funnel plot examining potential publication bias for EA IgG in RA patients 
and controls (OR). OR – odds   ratio. 
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Appendix E. Baseline Characteristics and Measurement Tools. 
Table E-1. Sample characteristics at baseline visit. 
 
All IA cohort,  
n=2519 
RA, n=2209  
(87.7%) 
UIA,  
n=310 
(12.3%) 
P-
value* 
Sociodemographic characteristics     
Age, mean (SD), years 54.7 (15.1) 54.7 (15.0) 54.7 (15.5) 0.98 
Female, n (%) 1791 (71.1) 1577 (71.4) 214 (69) 0.4 
Caucasian ethnicity, n (%) 2053 (81.5) 1803 (81.6) 250 (80.7) 0.7 
Education <= high school, n (%)  1051 (41.7) 945 (42.8) 106 (34.2) 0.004 
Never smoked, n (%) 1109 (44.2) 958 (43.6)  151 (49.2) 0.06 
Province     
Ontario 1127 (44.7)    
Quebec 908 (36.1)    
British Columbia 147 (5.8)    
Alberta 146 (5.8)    
Manitoba  66 (2.6)    
Nova Scotia 48 (1.9)    
Saskatchewan 47 (1.9)    
Newfoundland 30 (1.2)    
Disease characteristics at baseline     
Patient-reported symptom duration, 
mean (SD), months (from baseline 
visit) 5.4 (3.1) 5.4 (3.1) 5.7 (3.4) 0.06 
Physician-reported symptom duration, 
mean (SD), months (from baseline 
visit) 5.3 (3.0)  5.3 (3.0)  5.6 (3.1)  0.09 
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Tender 28 joint count, mean (SD), N 8.0 (6.6) 8.7 (6.7)  3.1 (2.8)  <0.0001 
Swollen 28 joint count, mean (SD), N 7.2 (6.0) 7.7 (6.1) 2.9 (2.6) <0.0001 
DAS28 (CRP) 3-variable, mean (SD), 
N 4.6 (1.3) 4.7 (1.3) 3.5 (1.0)  <0.0001 
DAS28 (ESR) 3-variable, mean (SD), 
N 4.9 (1.5) 5.1 (1.4) 3.7 (1.2) <0.0001 
ESR, mean (SD), mm/h 27.0 (22.6) 27.9 (22.9) 20.5 (18.8) <0.0001 
CRP, mean (SD), mg/l 14.4 (18.4) 15.1 (18.9) 8.8 (12.6) <0.0001 
HAQ DI, mean (SD), N 1.0 (0.7) 1.1 (0.7) 0.7 (0.6)  <0.0001 
RF positive, n (%) 1103 (44) 1045 (47.9) 32 (11.1) <0.0001 
ACPA positive, n (%) 958 (52.7) 928 (57.5) 30 (14.9) <0.0001 
Number of observations varied across the data. *all p-values are for UIA and RA 
comparisons. RA, rheumatoid arthritis; UIA, undifferentiated inflammatory arthritis; DAS, 
disease activity score; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; HAQ 
DI, Health Assessment Questionnaire Disease activity; RF, rheumatoid factor; ACPA, 
antibodies against citrullinated proteins.  
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Figure E-1. 1987 ACR classification criteria for rheumatoid arthritis. 
Criterion Definition 
A patient classified as RA if 4/7 criteria are satisfied. Criteria 1-4 must have been 
present for 26 weeks 
1. Morning stiffness 
Morning stiffness in and around the joints, lasting at least an 
hour before maximal improvement 
2. Arthritis of > 3 
joints areas 
> 3 joints areas simultaneously have had synovitis observed by 
a MD 
3. Arthritis of hand 
joints At least 1 area is swollen in a wrist, MCP or PIP joint 
4. Symmetric 
arthritis 
Simultaneous involvement of the same joint areas on both sides 
of the body 
5. Rheumatoid 
nodules 
Subcutaneous nodules, over bony prominences, extensor 
surfaces or juxta-articular regions 
6. Serum rheumatoid 
factor (RF) Positive RF 
7. Radiographic 
changes 
Radiographic changes typical of RA in posteroanterior hand 
and wrist radiographs 
MD – medical doctor; MCP – metacarpophalangeal; PIP – proximal 
interphalangeal 
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Figure E-2. 2010 ACR/EULAR classification criteria for rheumatoid arthritis.  
Target population: patients who (1) have at least one joint 
with clinical synovitis, and (2) the synovitis is not better 
explained by another disease 
                                  
Score 
Add score of categories A-D, score of > 6/10 is required to classify a patient as having 
definite RA 
A. Joint involvement (tender/swollen)   
1 large joint 0 
2-10 large joints 1 
1-3 small joints (with or without involvement of large joints) 2 
4-10 small joints (with or without involvement of large 
joints) 3 
> 10 joints (at least 1 small joint) 5 
B. Serology   
Negative RF/ACPA 0 
Low positive RF/low positive ACPA 2 
High positive RF/high positive ACPA 3 
C. Active phase reactants   
Normal CRP/ESR 0 
Abnormal CRP/ESR 1 
D. Duration of symptoms   
< 6 weeks 0 
> 6 weeks 1 
RF – rheumatoid factor; ACPA – antibodies against citrullinated proteins; CRP – C-
reactive protein; ESR – erythrocyte sedimentation rate 
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Figure E-3. Patients’ data collection schedule. 
Visit MD  RN 
Patient 
Questionnaire 
Physician 
Questionnaire 
Long 
Labs1 
Short 
Labs2 
Chest 
radiograph 
Hands/Feet 
radiographs 
TB 
test BMD 
Baseline X X X X X3 X X X 
  
   X   X 
3 months X X X X   X        
6 months X X X X   X   X    
9 months X X X X   X        
12 
months X X X X X     X 
 
  
At 6 
months X X X X   X     
 
  
At 1 year X X X X X     X    
1Complete blood counts, acute phase reactants, liver function tests, creatinine, cholesterol 
tests, RF, ACPA, any other tests (usually at baseline only) that diagnose RA; 2 Routine 
tests used to monitor RA therapy; 3At baseline visits, baseline test (long labs + extra labs); 
MD – physician exam; RN - nurse exam; TB - tuberculosis; BMD - bone minera l 
densitometry. 
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Figure E-4.  Disease activity score formula. 
DAS28 form (3-variable score) 
 Right Left 
 Swollen Tender Swollen Tender 
Shoulder     
Elbow     
Wrist     
MCP 1     
 2     
 3     
 4     
 5     
PIP 1     
 2     
 3     
 4     
 5     
Knee     
Subtotal     
Total Swollen  Tender  
MCP – metacarpophalangeal joints, PIP – proximal interphalangeal joints 
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Tender Joint Count (TJC) (0-28)  
Swollen Joint Count (SJC) (0-28)  
ESR (mm/first hour)/CRP (mg/dl)  
  
DAS28 = 0.56*(tjc28) + 0.28*(sjc28) + 0.70*Ln(ESR) *1.08 + 0.16 
DAS28 = 0.56*(tjc28) + 0.28*(sjc28) + 0.36*Ln(CRP+1) *1.10 + 1.15 
 
 
For free online calculator visit www.das28.nl  
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Figure E-5. Health Assessment Questionnaire Disability Index.  
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There are 3 steps to scoring the HAQ (with aids/help): 1) identify the highest subcategory 
score from each of the 8 categories. Adjust for use of aids/help by increasing the category 
score from 0 or 1 to a 2 if use of aids/help for that category (utilize table of companion 
aids/help for HAQ categories). If the category score is already a 2 or 3, no adjustment is 
made; 2) sum the category scores; and 3) divide the final sum by the number of categories 
answered to obtain the final HAQ score rounded to the nearest value evenly divisible by 
0.125. Requires a minimum of 6 categories answered; if less, do not score. Increasing 
scores indicate worse functioning, where 0 means no functional impairment, and 3 means 
complete impairment. 
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